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Summary
Although the progestins medroxyprogesterone acetate (MPA) and
norethisterone acetate (NET-A) are widely used in reproductive therapy, the steroid
receptors and their target genes involved in the actions of MPA and NET-A are not
well understood. Surprisingly, it had not yet been investigated whether doses of MPA
and NET-A used for contraception and HRT cause significant side effects through
various target genes via the glucocorticoid receptor (GR).
In this thesis results of in vitro studies showed that, MPA, like dexamethasone
(dex) and prog, significantly repressed tumour necrosis factor (TNF)-stimulated IL-6
protein production, and IL-6 and IL-8 promoter reporter constructs at the
transcriptional level in L929sA cells, via interference with nuclear factor KB (NFKB)
and activator protein-1 (AP-1) transcription factors. Like dex and prog, MPA did not
affect NFKB DNA-binding activity. Furthermore, unlike dex and prog, MPA did not
inhibit mitogen-activated protein kinase (MAPK) activity. The antagonistic effects of
the GR and progesterone receptor (PR) antagonist, RU486, as well as the MPA-
induced nuclear translocation of the GR, strongly suggest that the actions of MPA in
these cells are mediated at least in part via the GR. Although the mechanism was not
investigated as extensively as for MPA, NET-A was shown to repress IL-8 promoter
reporter activity very weakly relative to dex, MPA and prog in Hek293 cells stably
transfected with the rat GR. Furthermore, NET-A, like MPA, dex and prog did not
interfere with the DNA-binding activity of NFKB.
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Significant transactivation of a GRE-driven promoter reporter construct by
MPA and dex in L929sA via endogenous GR and COS-1 cells via expressed rat GR,
and by MPA, dex and prog in Hek293 cells via expressed rat GR was also observed.
In contrast, NET-A, unlike MPA, dex and prog showed no transactivation in Hek293
cells.
MPA, NET-A and prog were shown to compete with dex for binding to the
endogenous human GR in human lung carcinoma A549 cells. Similarly, MPA and
NET-A were shown to compete with dex for binding to expressed rat GR in COS-1
cells. MPA displayed a higher relative binding affinity than NET-A for the GR in both
systems, and a higher relative binding affinity than prog in A549 cells. Equilibrium
dissociation constants (Ki values) for MPA (Ki = 10.8 ± 1.1 nM), NET-A (Ki = 270 ±
1.3 nM) and prog (Ki = 215 ± 1.1 nM) towards the human GR in A549 cells were also
established. Furthermore, dose-response curves showed that MPA displays
significantly greater GC agonist potency and efficacy than NET-A and prog for both
transactivation of a synthetic GRE-reporter construct and transrepression of a
synthetic IL-8 reporter construct via expressed rat GR in Hek293 cells, as NET-A
showed no transactivation and very weak partial agonist activity for transrepression.
Based on these observations, MPA behaves as a GR agonist whereas NET-A is
proposed to be a weak antagonist. These results show that MPA and NET-A are not
alike and not the same as prog in their mechanism of action via the GR, which may
have serious health implications in vivo. Such insights may provide women and their
clinicians with more information to facilitate the selection of contraception or
reproductive therapy regimes with fewer side effects.
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vSamevatting
Alhoewel MPA en NET-A algemeen gebruik word in hormoontherapie, is dit
nie duidelik watter steroïedreseptore en teikengene betrokke is by die werking van
MPA en NET-A nie. Verrassend is dat geen studie nog gedoen is om te bepaal of die
dosisse van MPA en NET-A wat gebruik word in voorbehoeding en
hormoonvervangingsterapie (HVT), newe-effekte veroorsaak deur die
glukokortikoïedreseptor (GR) en verskeie teikengene nie.
In hierdie tesis is in L929sA selle aangetoon dat MPA, net soos
deksametasoon (dex) en prog, TNF-gestimuleerde IL-6 produksie onderdruk, en dat
IL-6 en IL-8 promoter-rapporteerderkonstrukte op transkripsionele vlak onderdruk
word deur middel van inmenging met NF-KB en AP-1 transkripsie-faktore. Net soos
dex en prog het MPA nie die DNA-bindingsaktiwiteit van NF-KB beïnvloed nie.
Anders as dex en prog het MPA egter nie MAPK aktiwiteit onderdruk nie. Die
antagonistiese effekte van RU486, asook die MPA-geïnduseerde translokasie van
die GR na die selkern, dui sterk daarop dat die effekte van MPA in hierdie selle ten
minste gedeeltelik deur die GR geskied. Alhoewel die meganisme vir NET -A nie so
breedvoerig bestudeer is as dié van MPA nie, is tog aangetoon dat, in Hek293 selle
wat stabiel getransfekteer is met die rot GR, die onderdrukking van die IL-8 promoter
deur NET-A baie swakker is as met dex, prog en MPA. Verder is daar ook gevind dat
NET-A, net soos MPA, dex en prog, nie kon inmeng met die DNA-bindingsaktiwiteit
van NF-KB nie.
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Beduidende transaktivering van 'n GRE-bevattende promoter-
rapporteerderkonstruk deur MPA en dex in L929sA en COS-1 selle, en deur MPA,
dex en prog in Hek293 selle, is ook gevind. Daarteenoor het NET-A, anders as MPA,
dex en prog, geen transaktivering in Hek293 selle getoon nie.
Verder moes die relatiewe bindingsaffiniteit (ewewigs-dissosiasiekonstantes)
van MPA, NET-A en prog vir die GR, asook die relatiewe sterkte en effektiwiteit vir
transaktivering en transonderdrukking van verskeie teikengene deur die GR, ook
bepaal word. Daar is gevind dat MPA, NET-A en prog meeding met dex vir binding
aan die endogene GR in mens longkarsinoom A549 selle. Soortgelyk hieraan is ook
gevind dat MPA en NET-A meeding met dex vir binding aan rot GR wat in COS-1
selle uitgedruk is. MPA het in beide sisteme 'n hoër relatiewe bindingsaffiniteit vir die
GR getoon as NET-A, asook 'n hoër relatiewe bindingsaffiniteit as prog in A549 selle.
Ewewigs-dissosiasiekonstantes (Ki waardes) vir MPA (Ki = 10.8 ± 1.1 nM), NET- A
(Ki = 270 ± 1.3 nM) en prog (Ki = 215 ± 1.1 nM) vir die mens GR in A549 selle is ook
bereken. Dosisrespons-grafieke het ook aangedui dat MPA 'n beduidend beter GC
sterkte en effektiwiteit as NET-A en prog het, vir beide transaktivering van 'n
sintetiese GRE-rapporteerderkonstruk en transonderdrukking van 'n sintetiese IL-8
rapporteerderkonstruk via rot GR wat uitgedruk is in Hek293 selle. Dit kon afgelei
word aangesien NET-A geen transaktivering en slegs baie swak gedeeltelike agonis-
aktiwiteit vir transonderdrukking getoon het. Op grond van hierdie waarnemings tree
MPA op as 'n GR agonis, terwyl dit lyk asof NET-A 'n swak antagonis is. Hierdie
resultate dui aan dat MPA en NET-A nie dieselfde is nie, en ook nie dieselfde
meganisme van werking deur die GR het as prog nie. Dit kan ernstige
gesondheidsimplikasies inhou in vivo. Hierdie insigte kan dus meer inligting aan
vroue en kliniese personeel verskaf om sodoende die keuse van voorbehoeding of
voortplantingsterapie met minder newe-effekte te vergemaklik.
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Format of this Thesis
The experimental work presented in this thesis is written up in manuscript
format for Chapters 1, 2 and 3. The thesis is thus composed of:
(i) a literature review on the appropriate background (Chapter 1);
(ii) two manuscripts reporting and discussing the undertaken experiments
and results (Chapters 2 and 3), each of which is followed by additional
results not included in the manuscripts (Appendixes 1 and 2); and
(iii) a discussion of the overall results with emphasis on the implications of the
study and future perspectives (Chapter 4).
The literature review presented in Chapter 1 will be submitted for review to Endocrine
Reviews.
The manuscript presented in Chapter 2 has been submitted for review to Molecular
and Cellular Endocrinology.
The manuscript comprising Chapter 3 will be submitted for review to Molecular
Pharmacology.
Although the collective "we" and "our" is often used in this thesis, as consistent with
manuscript format, the bulk of the experimental work was carried out by the
candidate, with only the following exceptions. In Chapter 2, Figures 3b, 6a, 6b and 7
were performed by one of our collaborators, Wim Vanden Berghe. In Chapter 3,
Figure 3a was carried out by Johann Riedemann.
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Aim and Scope of this Thesis
This study is divided into two parts, which are reported in Chapters 2 and 3.
The aim of the first part (Chapter 2) was to determine whether MPA, relative to dex
and prog, is able to repress interleukin gene expression, with a view to gaining a
better understanding of its immunosuppressive effects. There is evidence in the
literature that MPA has a high affinity and is an agonist for the GR (Teulings et aI.,
1980; Bojar et al., 1979; Feil and Bardin, 1979t Furthermore, the affinity of the rat
GR for MPA (Kd = 5.0 nM) is similar to that of dex (Kd = 4.1 nM) (Winneker and
Parsons, 1981), but higher than that for its endogenous ligand, cortisol (Kontuia et
al., 1983). Since GCs impact on virtually every aspect of the immune and
inflammatory response (Spangelo and Gorospe, 1995), we were prompted to study
the GC-like repressive action of MPA, relative to dex and prog. In Chapter 2
therefore, we were interested to determine the effects of MPA on IL-6 protein
production and IL-6 and IL-8 reporter construct expression and the mechanism
thereof. For this purpose, mouse fibroblast (L929sA) cells were used which contain
all the necessary machinery for pro-inflammatory cytokine synthesis. Furthermore,
since MPA has been implicated as a promising agent for the treatment of
autoimmune and/or inflammatory disease (Bamberger et al., 1999), we were also
prompted to investigate its dissociative GC properties in our model system. These
studies would contribute to gaining a better understanding of the molecular
mechanism of action of MPA, which would provide a molecular basis for
understanding its biological effects.
1 For references, see Chapter 1.
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The aim of the second part (Chapter 3) of the study was to compare the
relative GC agonist properties of MPA vs. NET-A (relative to dex and prog) for
transactivation of a synthetic GRE-reporter construct and transrepression of a
synthetic IL-8 reporter construct via expressed rat GR in Hek293 cells. These cells
were used because they express very low levels of endogenous receptors in the
absence of expressed GR, and are also responsive to nanomolar concentrations of
steroid. The aim was to also compare the relative binding affinity of MPA vs. NET-A
(relative to dex and prog) towards the GR in human lung carcinoma (A549) cells,
which contain endogenous GR. To date, no thorough comparison exists at the
molecular level of the mechanism of action of MPA vs. NET or NET-A. By comparing
these activities, the mechanisms by which they exert their effects should become
clearer. These findings would serve to highlight the differences between these
progestins, which would provide women and their clinicians with more information to
facilitate the selection of method of contraception or reproductive therapy regime.
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1Chapter 1
A review of the mechanism of action at the molecular level of
two synthetic progestins, medroxyprogesterone acetate and
norethisterone acetate
Dominique Koubovec and Janet Hapgood
Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland,
7602, South Africa.
Manuscript in preparation for submission.
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21. Manuscript
Summary
Medroxyprogesterone acetate (MPA) and norethisterone enanthate (NET-EN)
are two widely used progestin-only injectable contraceptives. In addition to their
contraceptive uses, both MPA and NET-A are used in the treatment of endometriosis
and in hormone replacement therapy (HRT), while MPA is used at higher doses in
cancer therapy and as supportive therapy in anorexia/cachexia syndrome. In this
review, the physiological effects of these progestins, as well as their regulation of
and/or binding to serum-binding proteins and steroidogenic enzymes is discussed. In
addition, their interactions with steroid receptors and their effects on various target
genes is reviewed at length. Both MPA and NET have been shown to interact with a
number of steroid receptors. MPA has a high affinity and is an agonist for the
glucocorticoid receptor (GR), androgen receptor (AR) and progesterone receptor
(PR), and has been shown to bind with low affinity to the mineralocorticoid receptor
(MR). NET has been shown to bind the PR and AR, and very low affinity has been
demonstrated for the GR and MR. Regarding the estrogen receptor (ER), MPA has
been shown not to bind the ER, whereas for NET, evidence of estrogenic activity is
unclear. It is therefore possible that MPA and NET exert therapeutic actions as well
as side effects via any of these receptors. Here we review the mechanism of action,
at the molecular level, of both MPA and NET via each of the above steroid receptors
on various target genes.
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31.1 MPA and NET-EN in contraceptive use
The injectable progestagen-only contraceptives, medroxyprogesterone
acetate (MPA) and norethisterone enanthate (NET-EN) (also referred to as either
norethindrone enanthate, norethisterone enantate or nuristerate), are the most widely
used conventional contraceptive agents used by women in South Africa, and are
both under current investigation for male contraception (Nieschlag et al., 2003).
Although MPA was developed as a contraceptive during the 1960s, and approved by
several countries in the late 1970s, it received FDA (Food and Drug Administration)
approval for contraceptive use only in 1992. Approval was delayed due to theoretical
but unproven links to breast cancer and alleged mutagenic properties (Kaunitz,
1994).
When used as an injectable contraceptive in women, MPA is administered as
a 150 mg aqueous suspension (referred to as Depo Provera) every three months
(MishelI, 1996), whereas NET-EN is administered as a 200 mg oily suspension every
two months (Garza-Flores et al., 1991). MPA, referred to as a true progestin, is a 21-
carbon series steroid, containing the pregnane nucleus whereas NET-EN is a 19-
nortestosterone progestin containing the androstane nucleus, which retains
androgenic activity (Darney, 1995). Both formulations are administered as
intramuscular injections. After injection, MPA is fairly stable and is itself the active
contraceptive compound. However, NET-EN and its acetate (norethisterone acetate,
NET-A) are hydrolysed to norethindrone (NET) and its metabolites, which together
with NET have contraceptive action (Stanczyk and Roy, 1990). MPA elicits its
contraceptive effects by abolishing peak or ovulatory gonadotropin levels and as a
consequence inhibits follicular maturation and prevents ovulation (Kaunitz, 2000;
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4Greydanus et aI., 2001). MPA also thins the endometrium and reduces glycogen
secretion to low concentrations, unable to support a blastocyst entering the
endometrial cavity (MishelI, 1996). In addition, MPA maintains the cervical mucus in
a thick and viscous state, which interferes with sperm penetration into the uterus
(Greydanus et aI., 2001). NET-EN has also been shown to block ovulation, (Bhowmik
and Mukherjea, 1988), but the primary contraceptive action of NET-EN involves
altering the content of cervical mucus to prevent sperm penetration (Bhowmik and
Mukherjea, 1987). MPA and NET-EN therefore, are highly effective contraceptive
agents in women due to their multiple sites of action. Interestingly, both MPA and
NET-EN, in a formulation with testosterone, are under current investigation for male
contraception. Testosterone esters that had been combined with injections of MPA or
NET-EN showed severe suppression of spermatogenesis, due to suppression of
gonadotropin levels, which are required for normal spermatogenesis (Nieschlag et
al., 2003).
Women receiving MPA by injection as a contraceptive typically have serum
concentrations of approximately 1 ng/ml for the duration of contraceptive treatment
(Misheil, 1996) i.e. about 2.6 nM. Levels of drug-related material have, however been
shown to reach as high as 25 ng/ml a few days post injection (Kirton and Cornette,
1974). Contraceptive doses of NET-EN have been reported to result in serum
concentrations of about 1.5-59 nM (Fotherby et al., 1983). As for most drugs, both
MPA and NET-EN have been shown to have several side effects including irregular
menses, amenorrhea, headaches, weight gain and acne (Kaunitz, 2000; Greydanus
et al., 2001; Benagiano et al., 1978; Darney, 1995). For MPA, dizziness, fatigue,
bloating of the abdomen or breasts, behavioural changes, reduced libido and
possibly decreased bone density have also been reported (Kaunitz, 2000; Greydanus
et al., 2001). Although the side effect profile of NET-EN is not as well defined as that
of MPA, it is assumed to be similar to but less severe than MPA, in particular the
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5shorter time lapse before return to fertility after cessation of treatment (Benagiano et
al., 1978; Koetsawang, 1991).
o
o
II
O-C-CH, 3
;:'
B oIIo -C-CH3
CH3I\,C=CH
A
H H
o
II
C-CH20H
CH3 ,OH
I' ".,CH3
c D
F H
o
Figure 1: The chemical structures of natural and synthetic progestins, and a
synthetic glucocorticoid. (A) medroxyprogesterone acetate; (B) norethisterone
acetate; (C) progesterone; (0) dexamethasone.
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61.2 Non-contraceptive uses of MPA and NET-A
Although MPA and NET-EN are widely employed for preventing pregnancy,
these progestins have non-contraceptive uses as well. MPA is used at higher doses
in cancer therapy (Etienne et al., 1992; Yamashita et al., 1996) and as supportive
therapy in anorexia/cachexia syndrome (Downer et al., 1993), while both MPA and
NET-A are used in the treatment of endometriosis (Irahara et al., 2001; Harrison and
Barry-Kinsella, 2000; Muneyyirci-Delale and Karacan, 1998) and in hormone
replacement therapy (HRT) (Brunelli et al., 1996; Taitel and Kafrissen, 1995). Doses
of MPA used for cancer therapy typically range between 500 and 1500 mg orally per
day for about 12 weeks (Blossey et al., 1984), for treatment of endometriosis about
50- to 100 mg/day (Harrison and Barry-Kinsella, 2000; Telimaa et al., 1989), while
those used for HRT are about 10 mg/day for about 11 days (Brunelli et al., 1996). It is
not clear from the literature what the typical serum concentrations of MPA are, in
wamen on HRT. Daily doses of 5 mg NET-A and 2.5 mg NET have been reported for
the treatment of endometriosis (Surrey and Hornstein, 2002; Surrey, 1999), whereas
HRT doses of NET range between 0.35- to 2.1 mg orally per day (Taitel and
Kafrissen, 1995). Wamen receiving the Activelle HRT regime (0.5 mg NET-A,
estradiol 1 mg) are reported to have peak serum concentrations of NET ranging
between 1.4- and 6.8 ng/ml (3.64- to 17.7 nM) (Activelle package insert reg. no.
33/21.8.2/0532, Novo Nordisk).
At high cancer therapy doses, MPA has potent glucocorticoid (GC)-like
effects such as significant inhibition of adrenal function (Blossey et al., 1984; Papaleo
et al., 1984; Lang et al., 1990) and immunosuppression (Yamashita et al., 1996;
Mallmann et al., 1990; Scambia et al., 1988). Doses of MPA used in HRT modify
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1996; Malarkey et al., 1997) and have also been shown to elicit anti-inflammatory
effects (Wakatsuki et al., 2002). Furthermore, when used in the treatment of
endometriosis, MPA has been shown to interfere with lipoprotein metabolism that
could expose the individual to an increased risk of cardiovascular disease (Telimaa
et al., 1989). Similarly, side effects of MPA and NET when used in HRT include
changes in the levels of lipids, lipoproteins and vasomotion, which may increase
cardiovascular risk in postmenopausal women (Sitruk-Ware, 2000). NET and MPA
may also be involved in the possible increased risk of the development of breast
cancer (Riis et al., 2002; Stahlberg et al., 2003). Furthermore, the National Heart,
Lung and Blood Institute (NHLBI) recently terminated prematurely a major clinical
trial, scheduled to run until 2005, on the risks and benefits of an HRT regime of
. combined estrogen and progestin (MPA) in healthy menopausal women, due to an
increased risk of invasive breast cancer. A separate Women's Health Initiative study
of estrogen alone continues unchanged because at this stage, the risks and benefits
of estrogen are still uncertain, suggesting that MPA may be causing the increased
risk. Furthermore, increases in coronary heart disease, stroke, and pulmonary
embolism were observed in participants on HRT (combined estrogen and MPA)
compared to women who were administered placebo pills. Although fewer cases of
hip fractures and colon cancer were reported, the overall health risks were found to
exceed the benefits (Rossouwet al., 2002). Recently published data by investigators
working on the same trial also suggested an increase in the risk of ovarian cancer
(Anderson et al., 2003).
A variety of other non-contraceptive benefits of MPA include a reduced risk of
endometrial cancer, iron-deficiency anaemia, pelvic inflammatory disease, and
ectopic pregnancy. With regard to endometrial cancer, a case-control study by the
World Health Organisation (WHO) published in 1991 found an 80% reduction in risk
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protection was noted to be more profound than the protection associated with oral
contraceptive use (Kaunitz, 2000). MPA is also used for the treatment of
dysmenorrhea, menorrhagia, ovulatory pain, pain associated with ovarian disease,
premenstrual dysphoria and perimenopausal symptoms (Kaunitz, 1998).
Furthermore, MPA is also considered to be appropriate for mentally handicapped
women who have menstrual hygiene problems. Finally, MPA has been associated
with hematologic improvement in women with sickle cell disease and reduced seizure
frequency in women with seizure disorders (Kaunitz, 2000). Although NET is not as
widely used in reproductive therapy as MPA, NET-A is used in the treatment of acne
(Zouboulis and Piquero-Martin, 2003).
1.3 Physiological effects of MPA and NET
1.3.1 Effects of MPA and NET on immune and adrenal function
On a physiological level, MPA, and to a much lesser extent NET, have been
shown to exert a number of effects on immune and / or adrenal function. In the rabbit,
early studies reported significant suppression of circulating antibody production due
to MPA treatment (5 mg daily), to the same extent as that demonstrated with cortisol
treatment (50 mg twice a week) (Hulka et al., 1965). Similarly, MPA was shown to
suppress the primary humoral antibody response in rabbits and also extended
survival of dogs with renal allografts as well as survival of rabbit skin allografts
(Turcotte et al., 1968). In contrast, MPA was shown to enhance antibody production
in mice in vivo and in vitro in cultures of splenocytes, bone marrow cells or lymph
node cells (Vermeulen et al., 2001). In the guinea pig, MPA decreased expression of
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against infection (Gomez et al., 1998).
Surprisingly, little research appears to have been carried out in humans on
the effects of MPA at contraceptive doses on immune or adrenal function. Two early
findings show that MPA increases cell-mediated immune reactivity in the skin
(Gerretsen et al., 1979) and has a profound effect on the efferent phase of the
immune response (Gerretsen et al., 1980). In addition, MPA was found to
compromise cell-mediated immune status in Bangladeshi women receiving these
compounds as injectable contraceptives (Majumder et al., 1987). Furthermore, Jones
et al., (1974) reported lowered baseline plasma cortisol levels in contraceptive users
of MPA. In a later study, Aedo et al., (1981) also showed that administration of a
single dose of MPA resulted in a slight but significant reduction of cortisol in normal
menstruating women. However, healthy, non-lactating Thai women who received
long term MPA were found to have no significant change in adrenal function
(Amatayakul et al., 1988).
At higher doses (up to 1500 mg orally per day), MPA has been shown to
cause significant inhibition of adrenal function (Blossey et al., 1984; Papaleo et al.,
1984; Lang et al., 1990; Hellman et al., 1976) and immunosuppression in patients
(Brunelli et al., 1996; Malarkey et al., 1997; Yamashita et al., 1996; Mallmann et al.,
1990; Scambia et al., 1988; Kurebayashi et al., 2003; Naglieri et al., 2002).
Furthermore, MPA was shown to significantly reduce the proliferative response of
peripheral blood mononuclear cells (PBMC) from cancer patients to
phytohaemagglutinin (PHA) (Mantovani et al., 1997). Similarly, MPA at 100 ng/ml
was shown to exert a significant inhibitory effect on lymphocyte response to mitogens
in healthy volunteers (Corsini and Puppa, 1982-1983). The above results are in
contrast to Gronroos and Eskola, (1984) who showed no effect of MPA on
'.
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lymphocyte proliferation or on the proportion of Tand B cells in endometrial cancer
patients. Furthermore, MPA at 0.2 I!g/ml has been shown to reduce levels of
interleukin-1 beta (IL-113), interleukin-6 (IL-6), tumour necrosis factor alpha (TNFa)
and serotonin (5-HT) produced in culture by PHA-stimulated PBMC from cancer
patients (Mantovani et al., 1997). In addition, treatment of serotonin-induced
myometrial smooth muscle cells with MPA resulted in a marked decrease in IL-1a
mRNA and protein levels (Lan et al., 1999). Other studies showed that MPA at 10.6 M
could inhibit l3-chemokine production in choriodecidual cells (Kelly et al., 1997) and
interleukin-8 (IL-8) production in endometrial explants and chorion cells (Kelly et al.,
1994). In contrast Arici et al., (1996a) found that MPA at 10.7 M increased the level of
IL-8 mRNA in human endometrial stromal (ES) cells.
Interestingly, MPA is widely used to facilitate infection of sexually transmitted
diseases in animal models. Kaushic et al., (2003) showed that MPA treatment (up to
2 mg/mouse) changed susceptibility and local immune responses to genital herpes
simplex virus type 2 (HSV-2) infection. Similarly, longer exposure to MPA lead to
poor innate and adaptive immune responses to HSV-2 that failed to protect mice
from subsequent genital challenges (Gillgrass et al., 2003). Also, expression of CD1,
a major histocompatibility class 1-like lipid antigen-presenting molecule was reduced
in endometrial epithelia of BALB/c mice after treatment with MPA (Sallinen et al.,
1999). In addition, significant changes were observed in the vaginal intraepithelial
leukocyte population of MPA contraceptive users, which was thought to reflect
altered local immune capacity (lIdgruben et al., 2003). Based on these and other
studies (Stephenson, 1998), MPA may exert a negative influence on local defence
mechanisms in the human female genital tract.
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Collectively, the above studies raise concern, as the potential exists for MPA
to exert not only local but also systemic immunosuppressive side effects in vivo.
There is evidence in the literature to suggest that the use of MPA as injectable
contraception has deleterious effects on human immunodeficiency virus (HIV) viral
shedding, but whether MPA influences susceptibility to HIV still remains a
controversial issue. When used as a contraceptive, MPA was found to increase HIV
viral shedding (Mostad et al., 1997) and HSV cervical shedding in HIV-infected
women (Mostad et al., 2000). Although Mostad et al., (1997) did not investigate the
molecular mechanism of these effects, they propose that they may be due to factors
such as direct effects on the virus, effects on local genital tract physiology or effects
on immune modulation of viral replication. Furthermore, progesterone implants,
which could mimic hormonally based contraceptives like MPA, were shown to thin
the vaginal epithelium and enhanced SIV (the simian form of the HIV virus) vaginal
infection in monkeys (Cohen, 1996; Marx et al., 1996). Interestingly, female sex
workers in Kenya who used MPA were found to have an increased incidence of HIV-
1 infection (Martin et al., 1998). However, other studies investigating the effects of
contraceptive use on the risk of HIV infection in women found no significant link (Mati
et al., 1995), or the results were inconclusive (Sinei et al., 1996; Daly et al., 1994).
Furthermore, a systematic review of the epidemiological evidence concerning
hormonal contraception and the risk of HIV transmission to women was inconclusive
as the quality of the studies reviewed was poor and inappropriate for statistical meta-
analysis (Stephenson, 1998).
In contrast to what is known for MPA, very little is known about the effects of
NET on immune function and to our knowledge, nothing to date on adrenal function.
Early studies in animal models on the effects of NET (5 mg daily) on the immune
system reported significantly prolonged survival of skin allografts and a moderate
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suppression of antibody production (Hulka et al., 1965). In the guinea pig, like MPA,
NET decreased splenic macrophage Fcgamma receptor expression, which impaired
the clearance of IgG-coated erythrocytes (Gomez et al., 1998). Furthermore, in
humans, NET like MPA compromised cell-mediated immune status in Bangladeshi
women receiving these compounds as injectable contraceptives (Majumder et al.,
1987).
1.3.2 Effects of MPA and NET on reproduction
Hypothalamic gonadotropin-releasing hormone (GnRH) is secreted by the
hypothalamus and binds to the GnRH receptor on the cell surface of pituitary
gonadotropes. There it activates intracellular signalling transduction pathways, which
stimulate the synthesis and release of luteinising hormone (LH) and follicle
stimulating hormone (FSH). These gonadotropins enter the systemic circulation to
regulate gonadal function, including steroid hormone synthesis and gametogenesis
(Ganong, 1991). Although the effect of MPA and NET on the regulation of GnRH
expression has not yet been determined, a few studies have investigated the effects
of MPA and to a lesser extent NET, on LH, FSH and steroid hormone levels. One
early study measured the peripheral blood levels of FSH, LH and estradiol after
intramuscular injection of a contraceptive dose of MPA in normal women. The levels
of all three hormones remained in the range of the early follicular phase of the
untreated cycle and ovulation was suppressed due to suppression of the LH peak.
Interestingly, no suppression of basal gonadotropin levels was reported in any of the
women, an effect which likely contributes to lack of menopausal-like symptoms in
women receiving MPA (Jeppsson and Johansson, 1976). In another study, sixteen
days after a 150 mg MPA administration, normally menstruating women showed a
decline in plasma levels of estradiol, progesterone and 17a-hydroxyprogesterone to
early follicular phase levels (Aedo et al., 1981). MPA administered at higher doses
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(daily doses of 2000 mg every 12 hours for 30 days, 60 mg daily for 14 days or 5 mg
daily for 12 days for each respective study) to post menopausal women resulted in
reduced plasma LH and FSH levels (Sala et al., 1978; Saaresranta et al., 2002;
Castelo-Branco et al., 1994), which increased after cessation of treatment (Castelo-
Branco et al., 1994). Similarly, MPA and NET administered at contraceptive doses to
post menopausal women significantly inhibited serum LH and FSH activity (Perez-
Palacios et al., 1981a). Furthermore, no LH surge or ovulation was detected in
patients involved in in vitro fertilisation studies who were administered 1 mg of NET
over a 5-day period (Letterie, 2000).
Furthermore, MPA and to a much lesser extent NET, have been shown to
influence expression of a number of genes involved in various endometrial functions.
Examples of such genes include tissue factor (TF) (Krikun et al., 2000), decidual cell-
expressed plasminogen activator inhibitor 1 (PAI-1) (Lockwood, 2001) and
transforming growth factor-beta (TGF-P) (Arici et al., 1996b). TF, a cell membrane-
bound glycoprotein, is responsible for the initiation of hemostasis and is associated
with decidualisation in the uterus. MPA at 10-7 M was shown to significantly enhance
TF gene transcription in ES cells, an effect mediated principally by Sp1 transcription
factor binding to its site on the TF promoter (Krikun et al., 2000), and likely involving
activation of epidermal growth factor receptors (EGFRs) (Lockwood et al., 2000).
Furthermore, decidual cell-expressed PAI-1 plays a role in preventing haemorrhage
during human pregnancy implantation. MPA plus estradiol, in the absence and
presence of EGFR, was shown to enhance PAI-1 protein levels 8- and 65-fold
respectively, in human ES cells (Lockwood, 2001). Another gene involved in
endometrial functions and regulated by MPA is TGF-p, which is believed to playa
role in the predecidualisation of human ES cells and in the completion of
decidualisation after blastocyst implantation. In this study, the regulation of TGF-
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131and TGF-133 mRNA levels in human ES cells in culture was investigated.
Treatment of ES cells with 1 nM MPA resulted in reduced levels of TGF-133mRNA,
yet only a small increase in the level of TGF-131mRNA was observed (Arici et aI.,
1996b). Reis et al., (2002) however, observed increases in TGF-133gene and protein
expression in endometrial samples from women having received higher MPA doses
of 10 mg/day. Interestingly in another study, MPA did not affect TGF-132and TGF-133
mRNA levels in MCF-7 human breast carcinoma cells, whereas a dramatic decrease
was observed with NET (Jeng and Jordan, 1991).
1.3.3 Effects of MPA and NET on reproductive cancers
There is evidence in the literature to suggest that the use of MPA as a
contraceptive does not increase breast cancer risk, and is associated with an 80%
reduction of endometrial adenocarcinoma, a level of protection greater than that
noted with oral contraceptives (Kaunitz, 1996). Similarly, Dillis and Schreiman, (2003)
postulated a suppressive effect of MPA on breast density in women receiving
contraceptive injections. Furthermore, MPA contraceptive use appears not to affect
the risk of epithelial ovarian cancer or cervical neoplasia (Kaunitz, 1996). However, in
contrast to the results of the above studies, recent clinical evidence suggests that
MPA in HRT use increases the risk of breast (particularly) and ovarian cancers
(Rossouwet al., 2002; Anderson et al., 2003), whereas no increased risk of
endometrial cancer has been reported (Anderson et aI., 2003). NET used in HRT has
been reported to protect against the hyperplastic effects of estrogen treatment on the
endometrium (Riis et aI., 2002) but whether it confers an increased risk of breast
cancer remains to be determined (Stahlberg et aI., 2003). To our knowledge, nothing
is known about the effects of contraceptive doses of NET on the development of
breast or uterine cancers. Further investigation is therefore required to determine
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whether NET (in contraceptive or HRT use) facilitates the development of
reproductive cancer in women.
A number of studies have been undertaken in cell lines and tissue samples to
determine further the effects and mechanisms of action of MPA and NET on uterine
and breast cancer. Consistent with the clinical evidence suggesting no deleterious
effect of MPA on the development of uterine cancers, MPA (at 10-8 M), unlike
estradiol, did not increase the expression of platelet-derived endothelial cell growth
factor (PD-ECGF), an angiogenic factor, in Ishikawa cells (Aoki et al., 2003). Further
in vitro evidence for the protective effect of MPA on the endometrium involves a
study on regularly cycling women treated with MPA (10 mg/day), which showed
suppression of c-fos expression in the human endometrial samples (Reis et al.,
1999). The protooncogene, c-fos is one of the putative mediators of estrogen-
induced endometrial proliferation. Although NET in HRT use has been shown to have
protective effects on the endometrium, its A-ring reduced derivatives (at 100 ~lg/100
g body weight) were able to significantly increase mRNA content of c-fos in
ovariectomised rats, although this increase was lower than that found with estradiol
treatment. These results indicate that NET administration might indirectly induce
estrogenic effects through the action of its 5a-dihydro and 3(3, 5a-tetrahydro
derivatives, an activity that may facilitate the development of uterine cancer
(Mendoza-Rodriguez et al., 1999). In contrast to the above study, and consistent with
its protective effects on the endometrium, in vitro studies analysing the effects of
NET-A on wingless-type mouse mammary tumour virus integration site family
member 7a (Wnt-7a) gene expression in normal endometrial epithelia (NEE) cells
showed for the first time upregulation of Wnt-7a gene expression in estrogen treated
NEE cells. Upregulation of Wnt-7a is thought to be associated with the antineoplastic
effects of progestins on the endometrium (Oehler et al., 2002). Although the above in
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vitro studies are consistent with the clinical evidence that MPA does not increase the
risk of endometrial cancer, the in vitro results for NET are inconclusive, and
inconsistent with the clinical evidence.
Although a number of in vitro studies have been carried out to determine the
effects of MPA and NET on breast cancer, for MPA the in vitro results do not
correlate with the recently available clinical evidence suggesting an increased risk for
HRT users. For NET the in vitro results are contradictory and definite conclusions
cannot be drawn. Cyclin 01, which is required for cell cycle progression in the G1
phase of the cell cycle, has been implicated in the pathogenesis of breast cancer.
After 24 hours of MPA (2.5 x 10-7 M) stimulation, an increased expression of cyclin
01 protein was observed, while at 72 hours the protein levels were barely detectable.
Similar results were obtained at the promoter level. In contrast to the recent clinical
evidence, the authors suggest that long-term MPA administration may therefore have
an inhibitory influence on the proliferative activity of breast cancer cells (Thuneke et
aI., 2000). Similarly, endogenous RNA expression levels of calcyclin were inhibited
by 10-7 M MPA in both human mammary carcinoma cells and hamster fibroblasts.
Calcyclin is a cell cycle-related gene, which seems to playa role in the pathogenesis
of some malignancies (Ghezzo et al., 1997). Furthermore, the level of parathyroid
hormone-related protein (PTHrP) expressed in breast cancer tissue is closely
associated with the incidence of bone metastasis. PTHrP mRNA expression was
investigated in breast tissues incubated for 24 hours with 10-5 M MPA. MPA was
shown to decrease PTHrP expression significantly, confirming its therapeutic effect in
the treatment of breast cancer with bone metastases (Sugimoto et aI., 1999). In a
study in MCF-7 cells, MPA was shown not to affect TGF-~2 and TGF-~3 mRNA
levels, whereas a dramatic decrease was observed with NET. This effect seen with
NET was accompanied by cell growth stimulation, which suggested that the
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differential regulation of TGF-f3 expression by NET might be partly responsible for the
growth stimulation induced by NET. It was further suggested that NET in
contraception might facilitate the development of breast cancer (Jeng and Jordan,
1991). In another study in MCF-7 cells, MPA and NET investigated in the range of
0.01 nM to 10 11Mdisplayed significant inhibition of cell proliferation between 20- and
25% for MPA and between 23- and 41% for NET over the whole concentration range
tested (Seeger et al., 2003). The above in vitro studies, in contrast to recent clinical
evidence for MPA, seem to indicate that MPA may reduce the risk of breast cancer,
while the effects of NET are not clear.
1.3.4 Effects of MPA and NET on skeletal function
Although the mechanism is poorly understood, a decline in bone mineral
density (BMD) in women with long-term contraceptive use of MPA has been reported
in a number of studies. This decrease in bone density tends to be greatest in women
who start MPA use at an early age, and in those whose duration of use exceeds 15
years (Cundy et al., 2003; Cundy et al., 1991; Cromer et al., 1996; Paiva et al., 1998;
Gbolade et al., 1998; Cundy et al., 1998; Scholes et al., 1999; Tang et al., 1999).
Attainment of peak bone mass during adolescence is one of the primary
determinants of osteoporosis risk in post-menopausal women. Concern therefore
exists among clinicians that adolescents using MPA are losing bone mineralisation at
a time in life when they should be experiencing a significant increase. Studies have
shown that BMD in groups of adolescent women using MPA as a contraceptive was
suppressed significantly (Cromer et al., 1996), especially in the femoral neck and in
the lumbar spine (Busen et al., 2003). MPA acts by inhibiting pituitary gonadotropin
secretion and thus reduces ovarian estrogen production (Jeppsson et al., 1982). The
cause of MPA-associated bone loss is not certain, but one plausible explanation is
that it is a consequence of estrogen deficiency. In the study by Cundy et al., (2003),
•
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estrogen replacement therapy arrested MPA-related bone loss in premenopausal
women with a minimum 2 year MPA use who had a below average baseline lumbar
spine BMD. However, according to Westhoff, (2002), the relationship between MPA
and changes in bone mineral density remains controversial despite a substantial
number of studies evaluating this potential association. This author also reported that
if bone density loss does occur in the presence of MPA, it is reversible and suggests
further that the benefits of MPA as a contraceptive outweigh the risks involving bone
mineral density (Westhoff, 2002). In addition, pre-menopausal women with
amenorrhea or abnormal menstrual cycles treated with MPA (10 mg/day for 10 days
per month) were shown to have improved spinal bone density (Prior et aI., 1994).
However, in HRT, MPA (20 mg/day) alone could not arrest spinal bone loss in
postmenopausal osteoporosis. Yet, when MPA (10 mg/day) was combined with
estrogen (0.3 mg/day), bone loss was reduced (Gallagher et aI., 1991). Similarly,
results from the Postmenopausal Estrogen/Progestin Interventions trial (PEPI)
showed that postmenopausal women receiving estrogens (0.625 mg/day) in
combination with MPA (10 mg/day for 12 days/month) exhibited an increase in bone
mass (The Writing Group for the PEPI, 1996). In addition, results from the Women's
Health Initiative trial demonstrated that estrogen (0.625 mg/day) plus MPA (2.5
mg/day) increased BMD and reduced the risk of fracture in postmenopausal women
(Cauley et al., 2003).
A number of studies have investigated the effects of NET oral contraceptive
use on bone turnover. Oral administration of contraceptive doses of NET (0.35
mg/day) was reported to protect against loss of bone mass in breast-feeding women
(Caird et aI., 1994). In addition, clinical studies have shown that an oral contraceptive
containing 20-35 !lg/day of ethinyl estradiol in combination with NET resulted in the
optimal bone-sparing effect in premenopausal women (DeCherney, 1996). Similarly,
women receiving a NET-containing oral contraceptive pill showed a 2.33% gain in
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BMD (Berenson et ai, 2001). Furthermore, the effects of NET in HRT have also been
investigated. On the one hand, NET-A has been reported to have positive effects on
postmenopausal bone metabolism, and has been shown to increase bone mass
more than alendronate, an effective candidate for both the prevention and treatment
of osteoporosis (Riis et al., 2002). Similarly, in the review by Taitel and Kafrissen,
(1995), a number of studies reported increased bone mass and BMD in
postmenopausal women treated with estradiol and NET-A. NET (5 mg/day) was also
shown to prevent bone loss in postmenopausal osteoporosis by decreasing bone
turnover (Horowitz et al., 1993). On the other hand, another study was unable to
show a consistent increase in markers of bone formation in postmenopausal women
treated with 5 mg NET-A for 5 weeks (Onobrakpeya et al., 2001). From the above
data, there appears to be sufficient evidence to support a link between MPA
contraceptive use and a reduction of bone mineral density. NET in oral contraceptive
formulation together with estradiol has also been reported to have positive effects on
bone mass. Whether injectable progestin only contraceptive doses of NET have
similar effects on bone requires further investigation. In HRT, both MPA and NET-A
in combination with estradiol appear to have positive effects on bone in
postmenopausal women.
1.3.5 Effects of MPA and NET on cardiovascular function
Recent randomised clinical trials have suggested that estrogen plus progestin
in HRT regimes does not confer cardiac protection and may increase the risk of
coronary heart disease in postmenopausal wamen (Rossouwet al., 2002). In
particular, the Women's Health Initiative included a randomised trial where
postmenopausal participants received daily doses of estrogen (0.625 mg) and MPA
(2.5 mg) and showed an elevated risk of coronary heart disease (Manson et al.,
2003). The use of sex steroids in contraception or HRT has also been associated
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with an increased risk of cardiovascular thromboembolic complications. Treatment of
vascular smooth muscle cells with MPA, in contrast to NET, upregulated
proteolytically activatable thrombin receptor (PAR-1) expression, which markedly
potentiated the vascular procoagulent effects of thrombin, an effect thought to be due
to the GC-like activity of MPA. In addition, long-term administration of MPA to
ovariectomised rats increased PAR-1 protein level in the arterial wall, which resulted
in increased responsiveness of isolated aortic rings to thrombin (Herkert et al., 2001).
Furthermore, progestin addition to estradiol replacement therapy may result in a
decline of beneficial effects on vasculature. MPA and NET were investigated for their
effects on various markers of endothelial function. MPA and NET did not interfere
negatively with estradiol-induced benefits including an increase in endothelial
prostacyclin production, a decrease in the synthesis of endothelin, PAI-1 and
adhesion molecule concentrations. MPA and NET also enhanced the positive effect
of estradiol on the precursor of matrix metalloproteinase-1. Interestingly however,
MPA unlike NET antagonised the estradiol-induced significant reduction of monocyte
chemoattractant protein-1. These results indicate that progestins may differ in their
effects on early stages of atherosclerosis (Mueck et al., 2002). NET-A (0.5 mg) in
combination with estradiol (1 mg) in HRT has been reported to result in increases in
blood pressure (Activelle package insert reg. no. 33/21.8.2/0532, Novo Nordisk). In
another study, NET-A in HRT was associated with an increased risk of stroke among
hypertensive but not normotensive women. The authors suggested that hypertensive
postmenopausal women should avoid using HRT regimes containing NET-A
(Lokkegaard et al., 2003). Furthermore, the effect of MPA and NET-A on cytokine
stimulated human umbilical venous endothelial cell (HUVEC) expression of adhesion
molecules was investigated. Both MPA and NET-A dose-dependently (10-10 to 10-8
M) increased expression of intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1). Since monocyte adhesion to endothelial cells is
an important initial event at the onset of atherosclerosis, the above results suggest
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that MPA and NET may contribute unfavourably to this disease (Tatsumi et aI.,
2002).
1.4 Targets of MPA and NET - mechanisms of action
In reviewing their mechanism of action, MPA and NET have been shown to
exert effects at various levels. Firstly, as both MPA and NET are known to bind to as
well as regulate serum levels of steroid-binding proteins such as corticosteroid-
binding globulin (CBG) (Pugeat et al., 1981; Misao et al., 1998a; van der Vange et
al., 1990) and sex hormone-binding globulin (SHBG) (Pugeat et al., 1981; Misao et
al., 1998b; Rodriguez-Aleman et al., 2000; Onobrakpeya et al., 2001; Fotherby,
1988; Biglia et al., 2003; Ylikorkala et al., 2003), they could potentially alter serum
concentrations and thus bioavailability of endogenous steroids to various target
tissues. Secondly, MPA and NET have also been shown to influence enzymes
involved in the steroidogenesis pathways (Lee et al., 1999; Anderson et al., 1990)
and thirdly, MPA and NET are able to regulate an array of genes by binding to
various steroid receptors (see sections 1.4.3 and 1.5). Below we briefly review what
is known on the molecular level on the effects of MPA and NET on serum-binding
proteins and steroidogenesis. Thereafter we focus in detail on reviewing the known
effects of MPA and NET via steroid receptors.
1.4.1 Serum-binding proteins
Once steroids enter the bloodstream, they immediately interact with several
serum-binding proteins, and a state of dynamic equilibrium is established that
determines how they become distributed between the various protein-bound fractions
and the non-protein bound or free fraction. Steroids that are bound to serum-binding
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proteins are unavailable to tissues, whereas steroids that are unbound are free to
diffuse from the blood into the cells of target tissues where they either get
metabolised or interact with specific steroid receptors. CBG and SHBG are low
abundance serum-binding proteins with high serum-binding affinity and specificity
(Hammond, 2002).
CBG is mainly synthesised in the liver (Scrocchi et al., 1993) and is the major
transport protein for natural GCs in all mammalian species including humans
(Hammond, 1990). Human CBG also displays a relatively high affinity for
progesterone and MPA (Pugeat et al., 1981; Hammond, 2002). The main function of
CBG is to transport and regulate the bioavailability of GCs to a range of target tissues
(Hammond, 1990). In this way, CBG may act as a buffer against potentially harmful
effects of elevated GCs on tissues (Breuner and Orchinik, 2002). CBG has also been
shown to influence metabolic clearance rates of GCs as the greater the fraction of
bound hormone, the slower the metabolic clearance (Siiteri et al., 1982). Little is
known about the effects of MPA or NET on CBG gene regulation. One study showed
that MPA at 10-6 M suppressed CBG mRNA expression in an endometrial cancer cell
line (Misao et al., 1998a), which could influence bioavailability of GCs to target
tissues. In contrast, oral contraceptive doses of NET resulted in an increase in serum
CBG levels in healthy women (van der Vange et al., 1990). Furthermore, in addition
to regulating CBG levels, MPA, to a greater extent than NET, has been shown to
bind to CBG (Pugeat et al., 1981). This may result in the displacement of
endogenous steroids and thereby increase their biological availability to tissues.
SHBG is produced by hepatocytes (Janne et al., 1998) and is a homodimeric
glycoprotein that binds testosterone and estradiol with high affinity (Hammond,
2002). The primary function of SHBG is to transport biologically active androgens
and estradiol in the blood, and it also plays an important role in regulating the free
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fraction of these steroids (Siiteri et al., 1982). Furthermore, several reports have
shown that SHBG can exit the blood circulation and enter the extravascular
compartments of various tissues (Bardin and Petra, 1980; Sinnecker et al., 1988).
This may regulate the local access of steroids (testosterone and estradiol) to target
cells that are not in the immediate vicinity of the blood supply. MPA has been shown
to influence SHBG gene regulation. In the Ishikawa human endometrial cancer cell
line, low (10-10 M) MPA concentrations in addition to estradiol (10-8 M) were found to
increase SHBG mRNA expression, whereas the addition of high concentrations (10-6
to 10-5 M) of MPA with or without estradiol (10-8 M) suppressed it (Misao et al.,
1998b). Similarly, serum SHBG concentrations investigated in postmenopausal
women decreased 58% with a daily treatment of 60 mg MPA for two weeks
(Saaresranta et al., 2000). In contrast, serum SHBG levels were significantly
increased in postmenopausal women treated with MPA at 2.5- to 10 mg daily in
combination with 2 mg per day estradiol valerate (Rodriguez-Aleman et al., 2000).
Both NET-A and NET have also been shown to influence SHBG levels in a number
of studies. Postmenopausal women treated with NET-A (5 mg/day) for 9 weeks
showed a significant decrease in SHBG levels (Onobrakpeya et al., 2001). Similarly,
increasing concentrations of NET antagonised the stimulatory effect of estrogen and
resulted in a reduction of serum SHBG concentrations (Fotherby, 1988). In contrast,
NET-A administration of up to 1 mg/day in combination with estradiol hemihydrate (2
mg/day) in postmenopausal women showed no variations in serum levels of SHBG
(Biglia et al., 2003). Furthermore, SHBG levels increased in osteoporotic elderly
women receiving 1 mg NET-A in combination with 2 mg estradiol over a period of
one year (Ylikorkala et al., 2003). In addition to regulating SHBG levels, NET, to a
greater extent than MPA, has been shown to bind to and displace [3H] testosterone
from SHBG (Pugeat et al., 1981; Fotherby, 1988; Darney, 1995; Activelle package
insert reg. no. 33/21.8.2/0532, Novo Nordisk). As discussed for eBG above, this may
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result in the displacement of endogenous steroids from SHBG, which may increase
their bioavailability to target tissues.
1.4.2 Effects of MPA and NET on steroidogenesis
The mechanisms by which MPA and NET inhibit human steroidogenesis are
not well investigated. Steroid hormones are derived from cholesterol by a stepwise
removal of carbon atoms and hydroxylation and are synthesised by cells of the
adrenal cortex (in the case of GCs and mineralocorticoids) and the gonads (in the
case of estrogens, progestins and androgens). For a thorough description on the
synthesis of steroid hormones, refer to Zubay, (1993) and Lee et aI., (1999). MPA
was investigated for its ability to inhibit the first three human enzymes in
steroidogenesis: the cholesterol side-chain cleavage enzyme (P450scc), the 17a-
hydroxylase/17, 20-lyase (P450c17), and type II 313-hydroxysteroid
dehydrogenase/isomerase (3I3HSDII). Briefly, P450scc converts cholesterol to
pregnenolone. P450c17 catalyses the 17a-hydroxylase reaction using pregnenolone
and progesterone as substrates to form 17-hydroxypregnenolone and 17-
hydroxyprogesterone respectively. P450c17 also converts 17-hydroxypregnenolone
to dehydroepiandrosterone (DHEA). 313HSD converts pregnenolone, 17-
hydroxypregnenolone and DHEA to progesterone, 17-hydroxyprogesterone and
androstenedione respectively. MPA at 10 to 100 11Mwas shown to have no effect on
P450scc activity in intact human choriocarcinoma JEG-3 cells. Similarly,
concentrations of up to 100 11MMPA failed to inhibit P450c17 expressed in yeast or
human adrenal microsomes. Finally, MPA (1 to 100 11M) showed substantial
inhibition of 313HSDII activity in yeast microsomes. These findings propose the
mechanism of action of MPA to be inhibition of human steroidogenesis (Lee et aI.,
1999). NET, however, was shown not to inhibit ovarian steroidogenesis in vivo and in
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vitro (Anderson et aI., 1990). To our knowledge, it is unknown whether NET has an
effect on adrenal steroidogenesis.
1.4.3 Steroid receptors
The steroid hormone receptor family is comprised of the glucocorticoid (GR),
androgen (AR), progesterone (PR), estrogen (ER) and mineralocorticoid (MR)
receptors. These are ligand-dependent transcription factors that display a high level
of similarity with regards to their structure and mechanism of action. In general, the
receptor members share a variable amino-terminal transactivation domain (NTD); a
central and well conserved DNA-binding domain (DBD), which interacts with the DNA
response elements, and a moderately conserved carboxy-terminal domain, which
contains the ligand-binding domain (LBO) to which the steroid hormone binds.
Furthermore, these receptors also possess transcriptional activation functions
located in the NTD and LBO. It is generally accepted that in the absence of ligand,
steroid receptors are coupled to heat-shock proteins and reside in the cytoplasm.
Once bound by steroids these (mostly cytoplasmic) receptors are activated and
translocate to the nucleus where they bind to specific DNA sequences, called
response elements, and subsequently regulate gene expression (Evans, 1988;
Beato, 1989).
1.4.3.1 GR mechanism of action
GCs are steroid hormones secreted from the adrenal glands in response to
various environmental stimuli. They mediate development and growth, regulate
glucose and mineral homeostasis and modulate stress, inflammatory and
immunological responses (Jenkins et aI., 2001). Due to their lipophilic nature, they
diffuse freely across cell membranes and exert their effects by binding with high
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affinity to the GR. In an unbound state, the GR resides in the cytoplasm and is
complexed with several different protein factors including heat-shock protein 90
(hsp90) (DeRijk et al., 2002) and immunophilins (Davies et al., 2002). Upon hormone
binding, receptor activation and phosphorylation occurs, resulting in substitution of
one immunophilin (FKBP-51) for another (FKBP-52), as well as recruitment of the
transport protein dynein. This GR-hsp90-FKBP-52-dynein complex then trans locates
from the cytoplasm to the nucleus where it dissociates, releasing GR to either
transactivate or transrepress specific genes (Davies et aI., 2002).
There are at least three mechanisms through which GCs can regulate gene
transcription. The first involves activation of genes through binding of GC-activated
GR homodimers to consensus sequences referred to as GC-response elements
(GREs) found in the promoters of various genes (Adcock, 2000; Webster and
Cidlowski, 1999; Newton, 2000). The consensus sequence for GRE binding is the
palindromic 15bp sequence GGTACAnnnTGTTCT, where n is any nucleotide
(Adcock, 2000). Many genes contain GREs in their promoters, including for example
lipocortin-1 (also known as annexin I), p11/calpactin binding protein (Flower and
Rothwell, 1994; Pitzalis et aI., 2002; Yao et aI., 1999), tyrosine aminotransferase
(TAT) (Sassi et aI., 1998), and mouse mammary tumour virus (MMTV) (Scheidereit
etal.,1983).
The second mechanism of GC-mediated regulation involves repression of
target genes through a direct interaction of GC-bound GR to variable negative GRE
(nGRE) sequences (ATYACnnTnTGATCn) within the promoter (Adcock, 2000).
Detailed footprinting revealed that the function of nGREs is to instruct GRs to bind as
monomers (Radoja et aI., 2000). nGREs are present in the promoters of various
genes, including the ACTH precursor gene, pro-opiomelanocortin (POMC) (Drouin et
al., 1993) and the corticotropin releasing hormone (CRH) gene (Maikoski and Dorin,
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1999). For the POMC gene, the mechanism for GR-mediated repression may involve
either protein-protein interactions with other factors (for example NUR77) or may be
due to steric hindrance due to the close proximity of GR binding to the TATA box and
transcription start site. This may block binding of other factors required for gene
activation (Murphy and Conneely, 1997).
Thirdly, GCs may inhibit gene expression by transcriptional cross-talk where
the GR mutually interferes with other signalling pathways such as those involving
activator protein-1 (AP-1), nuclear factor KB (NFKB), CCM T/enhancer binding
protein (C/EBP), cyclic AMP (cAMP)-responsive element-binding protein (CREB),
p53 and Smad (Webster and Cidlowski, 1999; Karin, 1998; De Bosscher et al.,
2003). This may require direct or indirect binding of the GR monomer to these
transcription factors. As this effect does not require direct binding of the GR to DNA,
the term "tethering GRE" is often used to describe these elements (Newton, 2000).
Many genes involved in the inflammatory response such as cytokines and
chemokines, which do not contain nGREs, have been reported to be repressed in
this way (De Bosseher et al., 2003).
1.4.3.2 GR isoforms
An additional level of complexity of steroid receptor action involves alternative
splicing of the human GR pre-mRNA, which generates two highly homologous
isoforms, known as hGRa and hGRI3. hGRa is a 777 amino acid ligand-activated
transcription factor which, when to bound to hormone, modulates the expression of
GC-responsive genes (Hollenberg et al., 1985; Bamberger et al., 1995). In contrast,
hGRI3 (742 amino acids) does not bind GCs and is transcriptionally inactive. hGRI3
has been shown to inhibit the effects of hormone-activated hGRa on a GC-
responsive reporter gene in a concentration-dependent manner (Bamberger et al.,
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1995). Furthermore, two forms of the hGRa, GR-A and GR-B, are produced by
alternative translation of the same mRNA. Both receptors were shown to display
similar subcellular localisation and nuclear translocation after ligand activation.
Interestingly, functional analyses of these splice variants showed that the shorter
hGR-B was nearly twice as effective as the longer hGR-A in transactivation, but not
in transrepression (Yudt and Cidlawski, 2001).
1.4.3.3 Functional domains of the GR
As described above briefly, steroid receptors have several functional domains
(see Figure 2). The NTD in the hGRa consists of amino acids 1-420, followed by the
DBD, which consists of amino acids 421-488. The LBD, at the carboxyl terminus,
consists of amino acids 527-777 and is separated from the DBD by a hinge region.
The LBD of both the hGRa and hGR(3 are identical up until amino acids 727,
whereas after that the structures begin to diverge (DeRijk et al., 2002). Within this
hinge region is the site of monomer interaction or the dimerisation domain. The GR is
folded in such a manner that two zinc fingers protrude from the surface enabling
interaction with DNA (Adcock, 2000). The two zinc fingers form a single structural
domain consisting of two a-helices, one adjacent to each zinc finger (Baumann et al.,
1993). Once binding to DNA has occurred, the NTD (also known as 11 or AF-1 for
activation function-1) is involved in transactivation of genes and may also be involved
in binding to other transcription factors (Adcock, 2000). In the human GR, there is
another transactivating domain (12 or AF-2), which also plays an important role in
nuclear translocation of the receptor (Adcock, 2000).
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Figure 2: A schematic representation of the structural and functional domains
of the glucocorticoid receptor (from Adcock, 2000).
1.4.3.4 AR, PR and MR mechanism of action
The AR, PR, MR and GR, display a high level of similarity with regards to
their structure and mechanism of action. Synthetic GREs, also referred to as steroid
response elements (SREs), are therefore able to mediate induction by progesterone,
androgens and mineralocorticoids, in addition to GCs, via the PR, AR and MR,
respectively. Furthermore, natural elements such as those found in the MMTV
promoter are also able to mediate induction by the above hormones, via their
respective receptors (Beato, 1989).
The AR and PR have also been shown to mediate transrepression of genes
via the same mechanism as the GR by tethering to other transcription factors. For
example, NFKB can be antagonised by the PR (Kalkhoven et al., 1996) and the AR
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(Palvimo et al., 1996; Bellida et al., 1995), resulting in suppression of genes. This
antagonism involves direct protein-protein interactions between the steroid receptors
and NFKB (Palvimo et al., 1996; Kalkhoven et al., 1996).
1.5 Mechanism of action of MPA and NET on target genes via
various steroid receptors
As both compounds are progestins, the contraceptive effects of MPA and
NET-EN are generally assumed to be mediated via the PR. However, MPA has also
been shown to bind with high affinity to the GR, AR, and PR (Teulings et al., 1980;
Bentel et al., 1999; Kemppainen et al., 1999; Bojar et al., 1979; Bergink et al., 1983;
Feil and Bardin, 1979) and has been shown to be an agonist for transactivation
(Bamberger et al., 1999; Bentel et al., 1999; Kemppainen et al., 1999; Mueller et al.,
2003; Gao et al., 2000), and an agonist for transrepression via these receptors
(Bamberger et al., 1999; Zhao et al., 2002). MPA has also been shown to bind to the
MR (Wambach et al., 1979). Binding and agonist activity for transactivation by NET
has been demonstrated for the PR and AR (Deckers et al., 2000; Bergink et al.,
1983; Bergink et al., 1985), and very law affinity has been shown for the GR (Kontuia
et al, 1983; Schoonen et al., 2000) and MR (Wambach et al., 1979). Regarding the
ER, MPA has been reported not to have estrogenic effects (Markiewicz and Gurpide,
1994) and has also been shown not to bind to the ER (Teulings et al., 1980; Bergink
et al., 1983). For NET, evidence of estrogenic activity is conflicting. On the one hand
and in contrast to MPA, NET (Markiewicz and Gurpide, 1994) and its A-ring reduced
metabolites (Mendoza-Rodriguez et al., 1999) have been reported to show intrinsic
estrogenic activity. Furthermore, a metabolite of NET (3(3, Sa-NET) has been shown
to bind to the ER (Chavez et al., 1985). On the other hand, NET has been reported to
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have no binding or transactivation activities via the ER (Schoonen et al., 2000;
Bergink et al., 1983).
Despite their widespread use and many side effects, the target genes and
precise molecular mechanisms of action of MPA and NET are not well defined.
Below we review what is known on the mechanism of action at a molecular level of
these two compounds via the GR, AR, PR and MR.
1.5.1 MPA and NET effects via the GR
A collection of data exists showing MPA to interact with the GR (Kontuia et
al., 1983; Teulings et al., 1980; Bojar et al., 1979; Selman et al., 1996; Bamberger et
aI., 1999; Winneker and Parsons, 1981). One study found that MPA displays
considerable binding affinity towards the receptor (42%, relative to 100% binding by
dexamethasone (dex), calculated from EC50 curves at the 50% competition level) in
human mononuclear leukocytes. Interestingly, in the same study the relative binding
affinity of the naturally occurring ligand, cortisol, to the receptor was significantly
lower (25%) than that of MPA (Kontuia et aI., 1983). Similar results from EC50 curves
for MPA binding to the GR were obtained in human renal cell carcinoma (Bojar et aI.,
1979) and human breast cancer cells where the molar excess of competitor (MPA)
that caused 50% displacement of radioactive ligand was estimated as a measure of
affinity of MPA for the GR (Teulings et al., 1980). A Kd value (31 nM), which is a
more accurate measure of binding affinity, was also obtained for MPA binding to the
GR in human mononuclear leukocytes, and was shown to be only 3 times higher
than that of dex (Kd = 10 nM) (Kontuia et al., 1983). In the beagle dog, a Ki value of
3.7 nM was calculated for MPA and was shown to be only 4-5 times higher than that
of dex, also demonstrating a relatively high affinity for the GR (Selman et aI., 1996).
In another study, the affinity of the rat GR for MPA (Kd = 5.0 nM) was found to be
Stellenbosch University http://scholar.sun.ac.za
32
similar to that of dex (Kd = 4.1 nM) (Winneker and Parsons, 1981). In contrast to
MPA, NET has been shown to bind with low affinity (0.1% relative to 100% binding by
dex, calculated from EC50 curves) and was also unable to displace [3H] MPA from
the human GR (Kontuia et aI., 1983). In another study similar results were obtained
where NET displayed very low binding activity (below 1%, where dex = 100%)
towards the human GR in leukemic IM-9 cells (Schoonen et aI., 2000). The above
results indicate that in contrast to the volume of data available for MPA, very little is
known about NET binding to the GR. Furthermore, no comparison of the relative
binding affinities of the two progestins has been reported. Further studies are
therefore required to determine precise Ki values for both MPA and NET towards the
GR.
The repressive influence via the GR of MPA and to a much lesser extent
NET, on in vitro functions of human lymphocytes has also been investigated.
Evidence for GC-like MPA effects on lymphocyte function includes a recent study
where MPA (at 2.5x10-7 M) was shown to repress transcription of a human
interleukin-2 (IL-2) promoter reporter construct, stimulated with phorbol ester (TPA)
and ionomycin, in normal human lymphocytes, to the same extent as dex. These
observed effects of MPA are likely to be mediated by the GR, as human lymphocytes
express GR but no PR, and very low levels of AR (below the detection limit of the
Western blotting assay). MPA at 2.5x10-7 M was also shown to repress transcription
of the IL-2 promoter construct stimulated with TPA and ionamyein, via co-transfected
GR in Jurkat T-Iymphoma cells. At the protein level, MPA at 2.5x10-7 M markedly
suppressed TPA and ionomycin-induced IL-1, IL-2 and IL-6 protein production in
normal human lymphocytes (Bamberger et aI., 1999). Furthermore, MPA, unlike
NET, has been shown to induce GC-like effects including inhibition of the proliferative
responses to the T-cell mitogens concanavalin A and phytohaemagglutinin (Kontuia
et aI., 1983). Since GCs impact on virtually every aspect of the immune and
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inflammatory response (Spangelo and Gorospe, 1995; Galon et al., 2002), MPA, and
possibly NET, may exert side effects due to their GC-like repressive action on many
other target genes such as IL-6 and IL-8, in addition to those reviewed above,
involved in immune function. Moreover, several genes involved in reproduction are
negatively regulated by GCs, and may also be targets for MPA, such as the genes
for the a-subunit of glycoprotein hormones (Chatterjee et al., 1991) and prolactin
(PRL) (Sakai et al., 1988). Furthermore, physiological concentrations of GCs have
been proposed to be essential and optimal for osteoblast proliferation and
differentiation. It has recently been argued that orally administered MPA at high or
contraceptive doses decreases bone density due to its significant GC activity. The
authors proposed that bone loss associated with MPA administration is caused by
decreased osteoblast differentiation as a likely result of MPA occupying the GR,
since increasing GR occupancy beyond that reached at normal GC concentrations
reduces osteoblast differentiation (Ishida and Heersche, 2002).
Since many of the side effects of conventional GCs used to treat inflammatory
or autoimmune diseases can be attributed to transactivation of GRE-driven
promoters (Imai et al., 1993; Brasier and Li, 1996), an important goal of
pharmacological and clinical research has been to identify GCs that discriminate
between transactivation and transrepression. Bamberger et al., (1999) showed that in
normal human lymphocytes, MPA (at 2.5x10-7 M) acts as a dissociated GC, since it
efficiently transrepresses phorbol ester-stimulated IL-2 and IL-6 transcription, but
only marginally activates transcription via GREs. Furthermore, in a cancer treatment
study, MPA (over a f O nM to 1 11Mdose-range) was also shown to elevate protein
expression of Nm23-H1, a metastasis suppressor, 3-fold in metastatic human breast
carcinoma cells via the GR and thought to involve GREs (Ouatas et al., 2003).
Although NET has been shown to display no transactivation activity towards the GR
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in leukemic IM-9 cells (Schoonen et al., 2000), it has not yet been established in this
or any other system whether it displays dissociative GC properties. Further work is
therefore required to characterise pharmacologically in terms of potency and efficacy
the effects of MPA vs. NET on GR-mediated gene regulation for both transrepression
and transactivation of various target genes in the same system.
1.5.2 MPA and NET effects via the AR
A number of studies show that MPA binds to and is an agonist for
transactivation via the AR (Bentel et al., 1999; Teulings et al., 1980; Bamberger et
al., 1999; Kemppainen et al., 1999; Hackenberg et al., 1993; Perez-Palacios et al.,
1983; Perez-Palacios et al., 1981a; Perez-Palacios et al., 1981b; Maclaughlin and
Richardson, 1979; Bergink et al., 1983). In the study by Hackenberg et al., (1993) the
Kd of MPA for the AR was determined as 3.6 nM in MFM-223 human mammary
cancer cells compared to a Kd of 0.18 nM for dihydrotestosterone (DHT), the
endogenous ligand for the AR. Similarly, the Kd of MPA for the cytosolic AR from rat
pituitary and hypothalamus was determined as 1.7 nM and 2.9 nM respectively
(Perez-Palacios et al., 1983).
The mechanism of AR activation by MPA has recently been investigated. A
two-hybrid protein transfection assay in Chinese hamster ovary (CHO) cells showed
that MPA (up to 1 ).lM) failed to promote an NHT and carboxy-terminal (NIC)
interaction of the AR, which is usually induced by high-affinity agonists and believed
to be inhibited by antagonists. MPA was therefore proposed to activate the AR
through a mechanism that does not involve the NIC interaction. Although not an
antagonist, MPA was also shown to inhibit the DHT-induced AR NIC interaction at
low concentrations (as low as 1 nM) in the same cells. Furthermore, MPA (at 0.1 nM)
was shown to be able to induce transcriptional activation of a MMTV-Iuciferase
Stellenbosch University http://scholar.sun.ac.za
35
reporter construct in CV-1 monkey kidney cells via the AR. Agonist potency tended to
parallel the ligand-induced NIC interaction as lack of ligand-induced NIC interaction
by MPA was associated with 100-fold higher MPA concentrations relative to DHT
necessary for transactivation (Kemppainen et al., 1999). In another study, MPA (at
2.5 x 10.7 M) was reported to transactivate a GRE-driven reporter construct via co-
transfected AR in Jurkat cells. In addition, MPA (at 2.5 x 10-7 M) was reported to
mediate transrepression of an IL-2 promoter reporter construct stimulated with TPA
and ionomycin, via co-transfected AR in the same cells (Bamberger et al., 1999).
Consistent with the presence of an androstane nucleus, which retains
androgenic activity (Darney, 1995), NET has also been shown to bind to and have
agonist activity for transactivation via the AR (Perez-Palacios et al., 1981a;
Schoonen et al., 2000; Deckers et al., 2000; Chavez et al., 1985; Bergink et al.,
1983; Bergink et al., 1985). In the studies by Schoonen et al., (2000) and Deckers et
al., (2000), the relative binding and relative agonist activity values for transactivation
of NET for the AR were relatively low: 3.2 and 1.1% relative to that of DHT,
respectively. Similarly, the Kd of NET for the AR was determined as 1.9 x 10-8 M
(8.1% relative binding compared to 100% binding by the synthetic androgen, R1881)
in rat prostrate cytosol (Chavez et al., 1985). Furthermore, when comparing MPA and
NET, both progestins showed similar relative binding affinities (8- and 7%
respectively, relative to 100% binding for DHT) for the AR in MCF-7 cells, yet in
cytosol fractions of the same cells MPA showed a higher binding affinity (29%)
relative to NET (17%) for the AR (Bergink et al., 1985). It is unclear from some of the
above data whether the relative binding activity was determined from Kd values or
from EC50 curves. To our knowledge, the transrepressive effects of NET via the AR
on target genes have not yet been investigated. In addition, very little is known about
the relative transactivation and transrepressive effects of MPA vs. NET via the AR. In
an early study, administration of either NET-EN or MPA, in contrast to progesterone,
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resulted in a significant inhibition of serum gonadotropin levels in postmenopausal
women. Although the mechanism is unclear, this effect was suggested to be
mediated via the AR (Perez-Palacios et aI., 1981a). Further pharmacological
investigation into the relative binding affinity and relative agonist potency for
transactivation and transrepression towards the AR of MPA vs. NET is required.
1.5.3 MPA and NET effects via the PR
Consistent with MPA being a synthetic progestin, it has been shown in a
number of studies to bind to the PR (Maclaughlin and Richardson, 1979; Bergink et
aI., 1983; Feil and Bardin, 1979; Zhang et aI., 2000; Selman et aI., 1996). In the
beagle dog, competition experiments for binding to the PR demonstrated that MPA
(Ki = 1.5 nM) had an affinity equal to that of Org 2058 (Ki = 1.6 nM) (16a-ethyl-21-
hydroxy-19-nor-4-pregnen-3, 20-dione), a synthetic high affinity progestin (Selman et
aI., 1996).
MPA has also been shown to be a PR agonist for transactivation via synthetic
SRE sequences as well as via natural promoter-reporter constructs for several target
genes involved in different physiological processes such as tumour development. In
Jurkat cells, MPA at 2.5 x 10-7 M was able to transactivate a GRE-driven reporter
construct via co-transfected PR (Bamberger et al., 1999). MPA (at 100 nM) was also
shown to increase vascular endothelial growth factor (VEGF) promoter construct
activity in endometrial adenocarcinoma cells co-transfected with either hPRA or
hPRB (different isoforms of the human PR) via three functional progesterone
response elements (PREs) identified in the VEGF promoter (Mueller et aI., 2003).
Similarly, in another study, MPA treatment (10-8 M) also increased VEGF levels in the
media of T47-0 human breast cancer cells via the PR. These results raise the
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possibility that increased angiogenesis in response to progestins may playa role in
cell growth or metastasis in some human tumours (Hyder et al., 1998).
Furthermore, MPA has been shown in many studies to playa significant role
in various endometrial functions via the PR. Insulin-like growth factor binding proteins
(IGFBPs) regulate insulin-like growth factor action, which is believed to playa role in
endometrial differentiation. MPA was shown to increase the promoter activity of
IGFBP-1 in ES cells co-transfected with either hPRA or hPRB. The induced activity of
IGFBP-1 was mediated through the progesterone response elements, PRE1 and
PRE2 (Gao et al., 2000). MPA (at 0.1 ~lM) has also been shown to increase the
activity of a deleted glycodelin-A (GdA) promoter reporter construct 3-fold in a human
endometrial adenocarcinoma cell line via the PR. GdA expression is highly regulated
and the protein is abundantly produced in the glandular cells of human endometrium.
Since GdA potentially inhibits fertilisation but enhances implantation, the timing of
GdA expression is critical for fertility regulation (Gao et al., 2001). This increase in
GdA expression by MPA may possibly playa role in its contraceptive mechanism of
action. Furthermore, MPA (at 10-6 M) was also shown to enhance decidual PRL gene
activation in the presence of elevated intracellular cAMP levels in human ES cells
(Brosens et al., 1999). PRL is a marker of decidualisation, which is a critical process
in the preparation of the uterus for blastocyst implantation and which involves stromal
cell differentiation. Similar results were obtained in the human endometrium in vivo,
where PRL expression (mRNA and protein level) was increased significantly after
treatment with MPA at 10 mg/day (Reis et al., 1999). This synergy between MPA and
cAMP on decidual PRL expression was postulated to be dependent upon cellular
levels of PR. Transient expression of steroid receptor co-activator 1e (SRC-1 e) but
not SRC-1 a facilitated the synergy between cAMP and MPA (Brosens et al., 1999).
Recent evidence revealed an increase in STAT5 in response to cAMP/MPA
treatment, which served to enhance PRL expression in human ES cells (Mak et al.,
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2002). Furthermore, MPA (at 10-8 and 10-7 M) suppressed mRNA expression of the
long form leptin receptor (OB-R (L)) in organ-cultured proliferative endometrial
specimens by 50%. This progestin-induced suppression was blocked by the addition
of the anti progestin RU486, indicating that in the human endometrium, MPA acts via
the PR to suppress functional OB-R (L) mRNA expression. MPA may therefore alter
the sensitivity of the endometrium to leptin, which is involved in the stimulation of
reproductive functions and possibly in early development (Koshiba et al., 2001).
NET has also been shown to bind to the PR (Bergink et al., 1983; Deckers et
al., 2000; Chavez et al., 1985; Kontuia et al., 1975). The relative binding affinity of
NET for the PR was determined as 22%, relative to 100% binding by Org 2058
(Deckers et al., 2000; Schoonen et al., 2000). Furthermore, when comparing MPA
and NET, both progestins have been shown to bind to the PR with almost equal
affinity (Kontuia et al., 1975). Similarly, in cytosol fractions of MCF-7 cells, MPA and
NET both showed similar binding affinities for the PR (44- and 38% respectively,
relative to 100% binding by Org 2058). However, in intact MCF-7 cells, NET showed
lower binding affinity (41%) than MPA (65%) for the PR, relative to 100% binding by
Org 2058 (Bergink et al., 1983). It is unclear from the above data whether the relative
binding activity was determined from Kd values or from EC50 curves. Furthermore,
NET has also been shown to have agonist activity for transactivation via the PR on
synthetic and natural promoter constructs of genes involved in various physiological
functions. NET was shown to induce a PRE2-TATA-CAT reporter vector transiently
transfected in CV-1 cells stably transfected with the rabbit PR, and this activity was
inhibited by RU486 (Pasapera et al., 2001). In CHO cells transfected with the MMTV-
luciferase reporter, NET showed about 12% transactivation activity relative to 100%
agonist activity of Org 2058 (Schoonen et al., 2000; Deckers et al., 2000). In another
study, NET at 10-8 M (like MPA) was also shown to increase VEGF in the media of
cultured T47-D cells (Hyder et al., 1998), an effect likely mediated via the three
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functional PRE elements located in the promoter (Mueller et aI., 2003). Furthermore,
0.1 11MNET (like MPA) was shown to increase the promoter activity of IGFBP-1 in
endometrial cells co-transfected with hPRA via PRE sites present in the promoter
(Gao et al., 2000).
Several genes regulated by MPA and/or NET via the PR are involved in a
range of physiological functions. Both MPA and NET-A were shown to dose-
dependently (10-10 to 10-8 M) increase expression of ICAM-1 and VCAM-1. This
increase was blocked by the addition of RU486, but not by hydroxyflutamide, an AR
antagonist, indicating that this stimulation was mediated predominantly via the PR
(Tatsumi et aI., 2002). Prolonged MPA exposure (10-7 M for 8 days) was shown to
repress RANTES (regulated on activation, normal T cell expressed and secreted)
transcriptional activity by 36% and protein production by 50% via the PR in human
ES cells. RANTES is a critical chemokine in the pathogenesis of endometriosis and
has been suggested to play an early role in the inflammatory response (Zhao et al.,
2002). Although the above studies shed some light on the mechanism of action of
MPA and NET via the PR on various physiological functions, further pharmacological
investigation into the relative binding affinity and relative agonist potency for both
transactivation and transrepression of MPA vs. NET via the PR is required.
1.5.4 MPA and NET effects via the MR
MPA, NET and NET-A have been investigated for their ability to bind to the
MR. Both synthetic progestins were less active relative to progesterone for
competing with [3H] aldosterone for cytoplasmic receptor binding in rat kidney. The
relative binding affinities were obtained from EC50 curves and determined as 4% for
MPA and <1% for both NET and NET-A, compared to 100% binding by
progesterone, an antagonist for the MR (Wambach et al., 1979). Further
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investigations are required to determine precise Ki values for the relative binding of
both MPA and NET to the MR. Furthermore, no comparison exists on the relative
agonist potency of MPA and NET for both transactivation and transrepression of
target genes via the MR. These findings may result in an improved understanding of
the relative effects of MPA and NET on blood pressure and in cardiovascular
disease.
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1.6 Conclusion
The synthetic progestins, MPA, NET-EN and NET-A are widely used by
millions of women in reproductive therapy. Although both progestins have been
shown to exert a range of side effects when used in vivo, very little is known about
their mechanism of action. The importance of investigating at the molecular level the
mechanism of action of synthetic progestins is highlighted by recent clinical evidence
showing that MPA increases the risk of the development of breast cancer in HRT
users (Rossouwet al., 2002). In addition, MPA used as contraception has also been
shown to increase viral shedding (Mostad et al., 1997), which raises concern as to its
impact on the spread of viral diseases. Clearly more research is required to
investigate the relative effects of synthetic progestins on immune function in the
reproductive tract. MPA, unlike prog, may also have damaging effects on
neurological processes (Nilsen and Brinton, 2003). Interestingly to date, the relative
binding affinity and relative agonist potency and efficacy (relative to each other and to
prog) of MPA and NET-EN (and NET-A) for transrepression and transactivation via
various steroid receptors as well as their effects on intracellular signalling pathways
has not yet been determined. Furthermore, their interactions with serum-binding
proteins as well as their effects on steroidogenesis requires further investigation.
These studies would be important in defining differences in the mechanism of action
of various synthetic progestins, and hence facilitate an informed choice of progestins
for reproductive intervention and therapy.
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2.1 Manuscript
Summary
Although medroxyprogesterone acetate (MPA) is used as an injectable
contraceptive, in hormone replacement therapy and in treatment of certain cancers, the
steroid receptors and their target genes involved in the actions of MPA are not well
understood. We show that MPA, like dexamethasone (dex), significantly represses TNF-
stimulated interleukin-6 (IL-6) protein production in mouse fibroblast (L929sA) cells. In
addition, MPA repressed IL-6 and interleukin-8 (IL-8) promoter reporter constructs at the
transcriptional level, likely via interference with nuclear factor KB (NFKB) and activator
protein-1 (AP-1). Furthermore, like dex, MPA does not affect NFKB DNA-binding activity.
We also observed significant transactivation by MPA of a glucocorticoid response
element (GRE)-driven promoter reporter construct in both L929sA and COS-1 cells. The
MPA-induced nuclear translocation of the glucocorticoid receptor (GR), as well as the
antagonistic effects of RU486, strongly suggest that the actions of MPA in these cells
are mediated at least in part via the GR.
Stellenbosch University http://scholar.sun.ac.za
75
Introd uction
Medroxyprogesterone acetate (MPA), a 17a-acetoxy-6a-methyl synthetic analog
of the naturally occurring 17a-hydroxyprogesterone, is one of the major conventional
contraceptive agents used in Southern Africa. It is administered as Depo Provera, by
intramuscular injection of an aqueous suspension of 150 mg every 3 months. MPA is
also used at higher doses for hormone replacement therapy (HRT) (Brunelli et al.,
1996), cancer therapy (Blossey et al., 1984; Etienne et al., 1992; van Veelen et al.,
1986; Yamashita et al., 1996) and for the treatment of endometriosis (Irahara et al.,
2001; Harrison and Barry-Kinsella, 2000; Telimaa et al., 1989). Doses for cancer
therapy typically range between 500 and 1500 mg orally per day for about 12 weeks
(Blossey et al., 1984), while those used for HRT are about 10 mg/day for about 11 days
(Brunelli et al., 1996). As for most drugs, Depo Provera has been shown to have several
side effects (Kaunitz, 2000; Greydanus et al., 2001). Furthermore, at high doses such as
those used in cancer therapy, MPA has been shown to have potent glucocorticoid (GC)-
like effects such as complete inhibition of adrenal function (Blossey et al., 1984; Papaleo
et al., 1984) and immunosuppression (Yamashita et al., 1996; Mallmann et al., 1990;
Scambia et al., 1988). Doses of MPA used in HRT have been shown to modulate
immune function in humans, selectively affecting various immune cell subsets (Brunelli
et al., 1996; Malarkey et al., 1997). Surprisingly, little research appears to have been
carried out in humans on the effects of contraceptive doses of MPA on immune or
adrenal function, although some early findings showed that, even at these low doses,
MPA may have significant effects (Gerretsen et al., 1979; Gerretsen et al., 1980; Jones
et al., 1974; Aedo et al., 1981). A better understanding of the molecular mechanism of
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action and relative potency of MPA for the steroid receptors would provide a molecular
basis for understanding its biological effects.
The receptors mediating the effects of MPA as well as their target genes are not
well defined. The actions of MPA are generally assumed to be mediated via the
progesterone receptor (PR). However, MPA has a high affinity for the glucocorticoid
receptor (GR), androgen receptor (AR) and PR (Teulings et al., 1980; Bentel et al.,
1999; Kemppainen et al., 1999; Bojar et al., 1979; Bergink et al., 1983; Feil and Bardin,
1979). Furthermore, the affinity of the rat GR for MPA (Kd = 5.0 nM) is similar to that of
dexamethasone (dex) (Kd = 4.1 nM) (Winneker and Parsons, 1981), but higher than that
for the endogenous ligand, cortisol (Kontuia et al., 1983). It is thus possible that MPA
may exert many of its therapeutic actions as well as side effects via any of these
receptors. For example, in tumour regression, MPA may act partly via the PR (Blossey
et al., 1984; Braunsberg et al., 1987), but predominantly via the GR (Bojar et al., 1979)
or the AR (Teulings et al., 1980).
Interleukin-6 (IL-6) is a multi-functional cytokine that is involved in immune and
inflammatory responses including acute phase reactions, and hematopoietic activities.
IL-6 is produced by a number of cells including fibroblasts, T cells and mononuclear
phagocytes. In immune responses, IL-6 is a growth factor for mature B cells and
induces their final maturation into antibody-producing plasma cells. IL-6 is also involved
in activation and differentiation of T cells (Feghali and Wright, 1997; Ershier and Keller,
2000). Interleukin-8 (IL-8) belongs to a chemotactic cytokine family and is responsible
for the chemotactic migration and activation of neutrophils, lymphocytes, monocytes and
other cell types at sites of inflammation (Mukaida et al., 1994; Feghali and Wright,
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1997). The promoters of the interleukin-6 (IL-6) and interleukin-8 (IL-8) genes both
contain a variety of binding sites for known transcription factors, including activator
protein-1 (AP-1) and nuclear factor KB (NFKB) (Ershier and Keller, 2000; Vanden
Berghe et aI., 2000). For IL-6 gene activation in response to tumour necrosis factor
(TNF), the main transcription factor involved is NFKB (Vanden Berghe et aI., 1998).
Furthermore, GC-mediated repression of IL-6 and IL-8 genes has been shown to involve
the GR (De Bosscher et aI., 2003). Although the precise molecular mechanism of gene
repression by GCs is still controversial, nuclear GR is believed to repress IL-6 gene
expression by interference with the activity of transcription factors NFKB and AP-1 at the
promoter level (Ershier and Keller, 2000; De Bosseher et al., 2000a). Recently, studies
have been initiated to investigate the effects of MPA on the immune system. Bamberger
et aI., (1999) reported that MPA represses transcription of a human interleukin-2 (IL-2)
promoter reporter construct in normal human lymphocytes, to the same extent as dex.
Furthermore, Mantovani et al., (1997) showed that MPA reduced levels of interleukin-1 ~
(IL-1B), IL-6, TNFa and serotonin (5-HT), produced in culture by activated mononuclear
leukocytes from cancer patients. Other studies showed that MPA can inhibit lymphocyte
proliferation in vitro (Kontuia et al., 1983; Mantovani et al., 1997), ~-chemokine
production in choriodecidual cells (Kelly et aI., 1997) and IL-8 production in endometrial
explants and chorion cells (Kelly et aI., 1994). In contrast Arici et aI., (1996) found that
MPA increased the level of IL-8 mRNA in human endometrial stromal cells. In the
current study we investigated the effects of MPA on TNF-induced IL-6 and IL-8 reporter
gene expression in a mouse fibrosarcoma cell line, L929sA, as well as the mechanism
thereof.
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Materials and methods
Cell culture, cytokines and inducing compounds
Murine fibrosarcoma L929sA and HeLa cells were maintained as previously
described (Vanden Berghe et al., 1998). COS-1 cells were cultured in high glucose (1
g/ml) DMEM supplemented with 10% fetal calf serum (Highveld Biologicals, South
Africa), 50 lU/mi penicillin and 50 ).Lg/mlstreptomycin (GibcoBRL). The origin and activity
of TNF has been described previously (Vanden Berghe et al., 1998). Staurosporine
(Calbiochem-Novabiochem International (San Diego, CA)) was stored as a 2 mM
solution in DMSO at -20°C. Dex, MPA, progesterone (prog), R5020 and RU486 were
purchased from Sigma Aldrich. R1881 was purchased from NEN™ Life Science
(Boston, MA). Hydroxyflutamide was obtained from Dr C. Tendler (Schering Plough
Research Institute, Kenilworth, NJ). Stock solutions were routinely dissolved in ethanol
or DMSO and stored at -20°C. RU486 and hydroxyflutamide were used at 2 x 10-6 M.
Plasm ids
The plasm ids p1168hIL-6Iuc+, p(IL-6KB)350hIL-6Iuc+, p1168(KBmut)IL-6Iuc+,
p(GREh50hluc+ and pAP-1luc have been described previously (Vanden Berghe et al.,
1998; Vanden Berghe et al., 1999a; Plaisance et al., 1997; De Bosscher et aL, 2000b).
The deleted IL-8 promoter variants, p546hIL-8Iuc+, p133hIL-8Iuc+, p98hIL-8Iuc+ were
kindly provided by Dr N. Mukaida (Cancer Research Institue, Kanazawa, Japan)
(Mukaida et al., 1990). The rat GR cDNA (pSVGR1) (Delauney et al., 1996), the human
PRB cDNA (PMT human PRB) and 2xGREtkluc (Delauney et al., 1996) were obtained
from Prof S. Okret (Karolinska Institute, Sweden). The pPGK~GeopbA (Soriano et aI.,
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1991) constitutively expressing a neomycin-resistantlp-galactosidase fusion protein
under the control of the pPGK promoter from the mouse housekeeping enzyme, 3-
phosphoglycerate kinase, was a kind gift from Dr P. Soriano (Fred Hutchinson Cancer
Research Centre, Seatle, WA).
Inductions and transfections
Stable transfection of L929sA cells has been described previously (Vanden
Berg he et al., 1998). L929sA cells were stably transfected with a plasmid of interest
together with the p-galactosidase expression plasmid, pPGKpGeopbA (Soriano et al.,
1991). For inductions, 1.5 x 105 cells per well were seeded in 24-well dishes twenty-four
hours before induction, such that they were 80% confluent at the time of the experiment.
The medium was removed and replaced by antibiotic-supplemented phenol red-free
medium (GibcoBRL) without serum, plus various test compounds. After induction, cell
culture supernatant was collected for quantification of secreted IL-6 (Landegren, 1984).
Cells were washed with DMEM without serum and lysed according to reporter gene
assay instructions. Luciferase and p-galactosidase reporter gene assays were
performed as described previously (Vanden Berghe et aI., 1998). Transient transfection
of COS-1 cells was performed either with FuGENE 6 (Roche Biochemicals) (according
to manufacturer's instructions) or by the calcium phosphate precipitation procedure
according to standard protocols. Briefly, cells were seeded 4 x 104 cells per well in 12-
well plates and transfected the following day with 5 fl9 2xGREtkluc and 2.5 fl9 pSVGR1
and pPGKpGeopbA respectively. Cells were then incubated with DNA precipitates for 24
hours. Thereafter, cells were washed twice with PBS and medium without serum was
added. Cells were incubated with test compounds for a further 24 hours followed by
harvesting with Reporter Lysis Buffer (Promega Luciferase Assay System). The p-
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galactosidase (Galacto-Star™ assay system) and luciferase assays (Promega
luciferase Assay System) were performed in a labsystems luminoskan RS
luminometer. luciferase activity was normalised to co-expressed p-galactosidase
activity to correct for differences in transfection efficiencies. Where indicated, the
Bradford assay was used to determine total protein concentration.
Electrophoretic mobility shift assay (EMSA)
1929sA and Hela cells seeded 3 x 105 per well in 6-well plates, were left
untreated or were induced with 2000 lU/mi TNF for 30 minutes, in the absence or
presence of 1 11Mdex, MPA or prog in phenol-red free medium (GibcoBRl) for two
hours. Total cell extracts were prepared using TOTEX buffer (20 mM Hepes/KOH pH
7.9,350 mM NaCI, 20% glycine, 1% NP 40,1 mM MgCI2, 0.5 mM EOTA, 0.1 mM EGTA,
2 mM Pefablock and 5 mM OTT). Equal amounts of protein were incubated for 30
minutes with an NFKB-specific 32P-labeled oligonucleotide (Vanden Berghe et al.,
1999b), for EMSA analysis as described in Plaisance et aI., (1997). Binding complexes
were analysed using Phosphoimager technology.
Immunofluorescence
The procedure was performed as described previously (Vanden Berghe et al.,
1999a). Essentially, 1929sA cells grown on coverslips were stimulated with test
compounds at the concentrations indicated for 30 min, followed by fixing and washing of
cells. Incubations with rabbit polyclonal anti-GR (H-300) antibody (SantaCruz) were
performed overnight at 4°C, followed by washing and incubation with secondary
antibody (goat anti-rabbit IgG biotin-conjugated antibody) (SantaCruz) at room
temperature for an hour. After washing, cells were incubated with an IgG streptavidin-
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Alexafluor marker (Molecular Probes) for one hour. Slides were then examined and
images recorded using a Zeiss Axiophot fluorescence microscope with CCD video
camera.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism software, using one-
way analysis of variance with either Bonferroni or Dunnett post tests. In most figures,
the letters a,b,c etc. are used to denote statistically significant differences, where all
those values which differ significantly (P<O,05) from others, are assigned a different
letter. In remaining figures, statistical significance of differences is denoted by *, ** or
***, to indicate P<O.05, P<O.01 or P<O.001, respectively.
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Results
MPA inhibits TNF-induced endogenous IL-6 protein production in L929sA cells.
The mechanism of GR-mediated repression of IL-6 has been extensively
investigated in L929sA mouse fibrosarcoma cells (De Bosscher et al., 2000a; Vanden
Berghe et al., 2000). We therefore carried out experiments using these cells as a model
cell line. Our aim was to determine the effects and mechanisms of action of MPA on
interleukin gene expression relative to the reference ligand, dex. Figure 1 shows that
MPA and prog, like dex, repress TNF-induced IL-6 protein secretion in L929sA cells,
although the inhibition by MPA and prog at 0.1 J.l.Mis less pronounced than that
observed for dex.
MPA represses TNF-induced expression of IL-6 and IL-8 promoter reporter
constructs, most likely via interference with the transcription factor NFKB.
To determine whether MPA can repress the IL-6 gene at a transcriptional level,
we investigated the effect of MPA on an IL-6 promoter-reporter construct, p1168h1L-
6Iuc+. Figure 2a shows that TNF-mediated induction of p1168hIL-6Iuc+, stably
integrated into L929sA cells, can be inhibited significantly by dex, MPA and prog. In
parallel to IL-6 promoter regulation, we also investigated the effect of MPA on the IL-8
promoter reporter construct, p546hIL-8Iuc+. Figure 2b shows clearly that MPA at 0.1
~LM,1 ~LMand 10 J.l.Mconcentrations can inhibit TNF-induced IL-8 promoter activity
significantly. MPA inhibits the promoter to a significantly greater extent than prog, yet
less efficiently than dex. This is particularly apparent at the 1 J.l.Mconcentration point for
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each test compound. Similar results were obtained with shorter IL-8 promoter variants
i.e., p133hIL-8Iuc+ and p98hIL-8Iuc+ (data not shown).
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Figure 1: Effect of dex, MPA and prog on TNF-induced IL-6 protein production in mouse
Cells were untreated or pre-treated with dex, MPA or prog in the presence of 2000 lU/mi TNF.
Steroid hormone was added two hours before TNF, for a total period of eight hours. After
induction, cell culture supernatant was collected for quantification of secreted IL-6. The combined
results of two independent experiments are shown, where each condition was performed in
triplicate. IL-6 protein for each test compound condition was normalised relative to protein in the
presence of TNF in the absence of test compounds, which was taken as 100%. The letters a,b,c
etc. are used to denote statistically significant differences, where all those values which differ
significantly (P<0,05) from others, are assigned a different letter.
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Figure 2: Effect of dex, MPA or prog on TNF-induced L929sA cells stably transfected with
either p1168hIL-6Iuc+ (A), p546hIL-8Iuc+ (B, C), or p(IL-6KBh50IL-6Iuc+ (0) promoter
reporter constructs, together with the ~-galactosidase construct, pPGK~GeopbA,
Dose-response curves for each dex-, MPA- and prog-treated L929sA cells, stably transfected with
the promoter construct p546hIL-8Iuc+ are shown in (C). Confluent L929sA cell monolayers were
untreated or pre-treated with dex, MPA or prog (the key in (A) also applies to (8) and (D)) in the
absence or presence of 2000 lU/mi TNF. Steroid hormone was added two hours before TNF, for a
total period of eight hours, after which cells were lysed and assayed for luciferase and ~-
galactosidase expression. Luciferase/ê-qalactosldase activity for each test compound condition
was normalised relative to the activity of the reporter in the presence of TNF and in the absence of
test compounds, which was taken as 100%. For (A), (8) and (D), the combined results of two
independent experiments are shown, where each condition was performed in triplicate. For (C)
the results shown are representative of four independent experiments, where each condition was
as for Figure 1.
performed in triplicate, and where a representative experiment is shown. The letters a.b,c etc. are
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Ligand dose-response curves for transrepression were determined for the
p546hIL-8Iuc+ reporter construct stably integrated into L929sAs. Figure 2c shows a
representative dose-response curve for MPA, dex, and prog, and Table 1 shows the
EC50 (defined as potency) and maximal repression (defined as efficacy) values
extrapolated from four experiments. Results confirm that MPA represses the IL-8
promoter significantly more potently than prog (p<0.05), but less potently than dex
(p<0.05). The maximal repression values for MPA and prog are similar (about 60%), but
less than that for dex (about 80%), showing that both these compounds act here as
partial agonists for transrepression.
As NFKB is a crucial transcription factor involved in TNF-mediated IL-6 and IL-8
gene induction (Mukaida et aI., 1994; Vanden Berghe et aI., 1998), we further
investigated whether our results could be mimicked with the synthetic promoter reporter
construct p(IL-6KB)350hIL-6Iuc+, containing three NFKB sites in front of a minimal IL-6
promoter, stably transfected in L929sA cells. Figure 2d shows that MPA at 0.1 11M,1 11M
and 10 11Mcan significantly inhibit the TNF-induced activation of the p(IL-6KB)350hIL-
6luc+ construct. Furthermore, MPA represses the promoter significantly more efficiently
than prog, but less effectively than dex, similar to our results obtained with IL-6 and IL-8
reporter promoter constructs.
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Potency (EC50) and efficacy (MAX) for transrepression (A) and transactivation (B)
A
EC50 (+/- SEM) MAX (+/- SEM)
DEX 2.2X10-tl (1.2) 19.7 (0.7)
MPA 9.0x10-a (1.4) 40.6 (1.5)
PROG 4.7x10-7 (1.4) 39.5 (1.8)
B
EC50 (+/- SEM) MAX (+/- SEM)
DEX 5.6x10-tl (1.3) 11.9 (0.9)
MPA 9.2x10-tl (1.3) 5.7 (0.2)
PROG 9.3x10-r (1.6) 1.9 (0.09)
Table 1: A) EC50 (M) and maximal values for transrepression (% activity relative to no test
compound, taken as 100% activity) were extrapolated from dose-response curves for each dex-,
MPA- and prog-treated L929sA cells stably transfected with the promoter reporter construct
p546hIL-8Iuc+ as shown in Figure 2C. MPA vs DEX p<0.05; MPA vs PROG p<0.05.
B) EC50 (M) and maximal values for transactivation (relative arbitrary units) extrapolated from
dose-response curves for each dex-, MPA- and prog-treated L929sA cells stably transfected with
the promoter reporter construct p(GRE)250hluc+ as shown in Figure 5A. MPA vs DEX p>0.05;
MPA vs PROG p<0.05.
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MPA inhibits a staurosporine (STS)-induced AP-1-driven minimal IL-6 promoter.
To determine whether the inhibitory action of MPA also affects AP-1 activity, we
transfected L929sA cells with an IL-6 promoter reporter gene variant with a mutated KB
site. STS was used to induce this promoter, which has lost its TNF inducibility but still
responds to STS via AP-1 dependent gene expression (Vanden Berghe et aI., 1999a).
Figure 3a shows that MPA at 0.1 flM, 1 flM and 10 flM can significantly repress STS-
induced promoter activity, while prog is significantly less potent than MPA. These results
were further strengthened with the synthetic reporter construct pAP-1Iuc, containing
three AP-1 sites in front of a minimal promoter, which mimics the response obtained with
the NFKB mutated Il-6 promoter (Figure 3b).
MPA does not interfere with the DNA-binding activity of NFKB.
Different mechanisms have been proposed to account for inhibition of NFKB
activity in response to anti-inflammatory drugs, which could interfere with cytoplasmic
(inhibitory protein KB (IKB) turnover) or nuclear (NFKB DNA-binding) events (Vanden
Berghe et aI., 2000). Previous studies have demonstrated that the GR represses NFKB-
driven genes without affecting DNA-binding activity of NFKB (De Bosseher et al., 1997;
Vanden Berghe et aI., 1999b). Since MPA has a high affinity for the GR, we were
interested to compare its effects relative to dex at the NFKB DNA-binding level. Figure 4
shows the results of a gel shift experiment in 1929sA cells where 1 flM MPA and prog,
like dex, had no effect on the DNA-binding activity of NFKB. Similar results were
obtained for Hela cells (data not shown).
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Figure 3: Effect of dex, MPA or prog on STS-induced L929sA cells stably transfected with
the promoter construct p1168(kBmut)IL6Iuc (A) and pAP-1luc (B) together with the p-
galactosidase expression vector pPGKpGeopbA. Confluent L929sA cell monolayers were
untreated or pre-treated with dex, MPA or prog in the absence or presence of 60 nM STS. Steroid
hormone was added two hours before STS, for a total period of eight hours, after which cells were
lysed and assayed for luciferase and p-galactosidase expression. Luciterase/ê-qatactosidase
activity for each test compound condition was normalised as for Figure 2. For (A) the combined
results of two independent experiments are shown, where each condition was performed in
triplicate. For (B) the results shown are representative of three independent experiments, where
each condition was performed in duplicate, and where a representative experiment is shown. The
letters a,b,c etc. are as for Figure 1.
Stellenbosch University http://scholar.sun.ac.za
90
TNF + + + +
DEX + +
MPA + +
Prog + +
p50p65
RBP-JK
2 3 4 5 6 7 8
Figure 4: Effect of dex, MPA and prog on NFKB-DNA binding.
L929sA cells were untreated or pre-treated with 1 ~LMdex, MPA or prog for two hours in the
absence or presence of 2000 lU/mi TNF for 30 minutes. Total cell extract was incubated with an
NFKB-specific oligonucleotide and protein-DNA complexes were analysed in an electrophoretic
mobility shift assay (EMSA). The result shown is typical of two independent experiments. RBP-JK
is the constitutively expressed recombination binding protein.
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MPA exhibits transactivation potential on a GRE-dependent reporter gene.
To determine whether MPA acts as a dissociated GC, we performed
transactivation studies using L929sA cells stably transfected with the promoter reporter
construct p(GREh50hluc+, consisting of two copies of a GRE in front of a minimal IL-6
promoter (Vanden Berghe et al., 1999b). Figure 5a shows dose-response curves for
MPA, dex, and prog, and Table 1 shows the EC50 (potency) and maximal (efficacy)
values extrapolated from each curve. Although MPA and dex achieve different levels of
maximal induction, with dex exhibiting a greater efficacy, their EC50 values are not
significantly different (MPA vs dex, P>O.05). However, MPA, a partial agonist here for
transactivation, is significantly more potent and has a greater efficacy than prog (MPA
vs prog, p<O.05). Transactivation studies were also performed on COS-1 cells
transiently transfected with a 2xGREtkluc reporter construct (containing two copies of a
GRE upstream of the tk promoter) with and without rat GR eDNA, in the presence of
steroid hormone. Results show that MPA, like dex, is able to transactivate the reporter at
nanomolar ligand concentrations, which are typically observed in the serum of women
using MPA as a contraceptive (MishelI, 1996) (Figure 5b). Furthermore, the latter effect
was clearly dependent on the presence of the GR (Figure 5b).
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Figure SA: Effect of dex, MPA or prog on L929sA cells stably transfected with the promoter
construct p(GRE)250hluc+ together with the f3-galactosidase construct, pPGKf3GeopbA.
Confluent L929sA cell monolayers were untreated or treated with dex, MPA or prog for 24 hours,
after which cell lysate was harvested. The combined results of two independent experiments are
shown, where each condition was performed in quadruplicate.
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Figure SB: Effect of dex, MPA and prog on COS-1 cells transiently transfected with 5f-lg
2xGREtkluc and pPGK~GeopbA, with or without 2.5f-lg pSVGR1. Cells were incubated the
following day for 24 hours with or without 2.6 nM test compounds and lysate was harvested. The
results shown are typical of three independent experiments. The letters a,b,c etc. are as for Figure
1. Luciterase/ê-qalactosldase activity for each test compound condition was normalised relative to
the activity of the reporter in the absence of test compounds. For A, this value was taken as 1.
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The effects of MPA in L929sA cells are mediated at least in part via the GR.
It is generally known that the GR, PR and AR are able to transactivate a GRE-
driven promoter in a ligand-dependent fashion. Thus receptor-specific antagonists were
used to investigate which receptor mediates the transactivation effects of MPA in
L929sA cells stably transfected with the (GRE)250hluc+ promoter reporter construct.
Hydroxyflutamide, an AR-specific antagonist, was unable to reverse the transactivation
observed with dex and could only slightly (but not significantly) antagonise the effects
seen with MPA (Figure 6a). As a control, we found that R1881, an AR agonist,
significantly transactivates the reporter, while hydroxyflutamide significantly reverses this
transactivation (data not shown). Thus although the AR is indeed present in L929sA
cells, it does not appear to mediate transactivation by MPA. However, Figure 6b shows
that RU486, a PR and GR-specific antagonist, is able to significantly reverse
transactivation by dex and MPA, and marginally by prog, indicating that either or both of
these receptors are involved.
Since dex is specific for the GR, the observed effects of dex can be assumed to
be due to the presence of the GR. To determine whether PR is present in L929sA cells,
cells were treated with test compounds in the presence of the prog-specific agonist
R5020. We found that R5020 is unable to transactivate the reporter, indicating that PR
is either present at very low levels undetectable by this assay, present but inactive for
transactivation, or is altogether absent in L929sA cells (data not shown). In contrast, in a
control experiment in COS-1 cells, R5020 clearly stimulates transactivation of a
transiently transfected GRE-driven promoter in presence of co-transfected PR,
demonstrating that the PR ligand is active. Reciprocally, no transactivation was
observed in the absence of co-transfected PR (data not shown).
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Figure 6: (A) Effect of dex or MPA, alone or in combination with hydroxyflutamide (OHFL)
on L929sA cells stably transfected with the promoter construct p(GREh50hluc+. (8) Effect
of dex, prog or MPA, alone or in combination with RU486 (RU) on L929sA cells stably
transfected with the promoter construct p(GREh50hluc+. Cells were incubated with test
compounds for 24 hours, followed by lysis and determination of luciferase levels. Results are
expressed as relative activity, where the activity in the absence of test compounds was taken as
1. The results shown are representative of two (A) or three (8) independent experiments, where
each condition was performed in quadruplicate, and where a representative experiment is shown.
differences is denoted by *, ** or ***.
For (A), the letters a,b,c etc. are used, as for Figure 1. For (8), statistical significance of
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To confirm the involvement of the GR in our observed effects of MPA in L929sA
cells, we performed GR-Iocalisation studies assessed by immunofluorescence assays.
In the absence of test compounds, the GR is localized mainly in the cytoplasm, whereas
some GR can also be observed in the nucleus, possibly due to phenol red effects or
trace amounts of steroid present in the serum. However, upon incubation with MPA, a
substantial increase in nuclear GR can be observed, with a concomitant decrease in
cytoplasmic GR (Figure 7). These effects can clearly be reversed by RU486 (data not
shown). Similar effects were recorded for dex (data not shown). Taken together, these
results strongly suggest that MPA exerts its effects in these cells at least in part via the
GR.
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Figure 7: Effect of MPA on GR localisation in L929sA as revealed by immunofluorescence
assay. Cells were stimulated with MPA for 30m in followed by fixing and washing of cells.
Incubations with polyclonal anti-GR (H-300) antibody were performed overnight at 4°C followed by
incubation with secondary antibody (goat anti-rabbit IgG biotin-conjugated antibody). IgG
Streptavidin-Alexafluor marker was used for visualization.
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Discussion
Our results show that MPA represses both TNF-induced IL-6 protein and
promoter reporter activity in our model cell line, L929sA (Figures 1 and 2a). At the
protein level, we observed repression down to approximately 5-8% by both dex and
MPA, whereas activation of the corresponding promoter reporter construct was
repressed to only 50%. The greater degree of repression at the protein level could be
due to post-transcriptional effects. We also showed that MPA represses synthetic
promoter reporter constructs, consisting of either three NFKB responsive elements, or
three AP-1 elements coupled to a minimal promoter (Figure 2d and Figure 3b,
respectively), consistent with a mechanism involving interference with NFKB and AP-1
activity. In analogy with IL-6, MPA can repress IL-8 reporters, to a lesser extent than
dex, but more efficiently than prog (Figure 2b). Consistent with this trend were the EC50
and maximal repression values extrapolated from ligand dose-response curves
established for the p546hIL-8Iuc+ reporter construct stably integrated into L929sA cells
(Table 1, Figure 2c). To our knowledge, this is the first report showing repression by
MPA of IL-8 promoter activity. Towards further investigating the mechanism of
repression of the IL-6 and IL-8 promoters by MPA, we tested whether MPA has any
effect on NFKB DNA-binding. MPA treatment of TNF-induced L929sA cells (Figure 4)
and HeLa cells (data not shown) could not disrupt DNA-binding by NFKB. This result is
consistent with previous reports showing that the GR does not disrupt DNA-binding by
NFKB in vitro (De Bosscher et al., 1997; Vanden Berghe et al., 1999b; Nissen and
Yamamoto, 2000) and in vivo (Nissen and Yamamoto, 2000).
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When assessing the dissociative properties of MPA as compared to dex in
L929sA cells, the fold differences relative to dex for transrepression compared with
transactivation were found not to differ substantially. MPA and dex display a similar
transactivation potential (1.6-fold difference in ECSO values) and only a four-fold
difference with regards to their relative transrepression potency (Table 1). With respect
to maximal effects, MPA displayed about 26% lower efficacy relative to dex for
transrepression (Figure 2c, Table 1), and approximately 50% lower efficacy relative to
dex for transactivation (Figure Sa), illustrating that MPA is a partial agonist for both
transactivation and transrepression in these cells. Hence, MPA did not exhibit
dissociated GC properties in our experimental model system. However, in the studies by
Bamberger et aI., (1999) and Bamberger and Schulte, (2000), MPA behaved as a
dissociated GC, as it only marginally transactivated a GRE-reporter construct in Hela
cells and in normal human lymphocytes. One explanation for these differences may be
that cell type-dependent variations in the efficacy of MPA may, as has been shown for
GCs, be due to differences in receptor or cofactor expression levels, presence of
different receptor isoforms, and different components of the intracellular signalling
machinery (Wallace and Cidlowski, 2001; Schneikert et aI., 2000; Bamberger et aI.,
1996).
Our data strongly suggest that the effects of MPA on transactivation of a GRE
reporter in L929sA cells are largely mediated via the GR. Hydroxyflutamide, which acts
as an antagonist of the endogenous AR in L929sA cells, has no effect on MPA-
mediated transactivation in these cells (Figure 6a), suggesting that the AR is not
involved. In contrast, we show in Figure 6b that the transactivation effects of MPA via
endogenous receptors in L929sA cells can be fully reversed by the GR- and PR- specific
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antagonist, RU486. The absence of PR activity for transactivation using a strong PR
agonist, together with the RU486 results, suggest that only the GR, and not the PR is
involved. In addition, our immunofluorescence results show that MPA causes nuclear
translocation of the GR, strongly supporting a role for MPA in ligand-mediated activation
of the GR. In the case of transrepression, we are unable to exclude the involvement of
the PR. Although our results suggest these cells do not contain transactivation
competent PR, and although there are reports in the literature that PR is undetectable in
binding assays in these cells (Jung-Testas et al., 1976), we were able to detect PR
mRNA and protein in our cells by RT-peR and Western blotting, respectively (data not
shown). It is thus possible that the PR-A isoform, a poor activator of transactivation but a
potent activator of transrepression (Kalkhoven et al., 1996), is expressed and mediates
some of the transrepressive activity of MPA. Since it is well established that MPA does
not bind to the estrogen receptor (ER), we can exclude a role for the ER in
transrepression (Teulings et al., 1980).
Interestingly, the transactivation activity of prog is also reversed by RU486,
although not significantly (Figure 6b). Given that transactivation agonist activity of the
PR could not be detected in these cells with R5020, prog appears to act as a very weak
partial agonist for transactivation via the GR, with about a ten-fold lower potency than
MPA (Table 1), and a much lower efficacy (Figure Sa, Table 1) (16% of the maximal
activity of dex, versus 50% for MPA). However, prog is a relatively stronger agonist for
transrepression, showing approximately five-fold lower potency (Table 1) and similar
efficacy (Figure 2c, Table 1) to that of MPA (both about 25% less repression than dex).
It needs to be further investigated whether selective effects of PR isoforms could
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perhaps explain these differences in the relative efficacy and potency of prog for
transactivation versus transrepression.
In summary, our data show that MPA acts like a partial to full GC agonist in
repressing both IL-6 and IL-8 promoters, with a potency of about four-fold less than that
of dex (Table 1) and a similar (Figures 2a, 3a) to lower (Figures 2b, 2c, 2d, 3b) efficacy
than dex. Given the multiple functions of the IL-6 and IL-8 cytokines, our results suggest
that MPA may exert significant side effects via repression of these genes on various
biological processes including those involved in the immune response, such as B cell
maturation and T cell differentiation and activation, and bone metabolism and
differentiation (Feghali and Wright, 1997; Ershier and Keller, 2000; Mukaida et al., 1994;
Ishida and Heersche, 2002). Moreover, our results suggest that GC-like actions of MPA
via the GR, resulting in transrepression via NFKB or AP-1 transcription factors, or
transactivation via GREs, may be involved in regulating expression of several genes
involved in many physiological processes.
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Appendix 1
Data not included in manuscript
TNF-activated p38 and extracellular-regulated kinase (ERK) mitogen-
activated protein kinase (MAPK) pathways have been shown to contribute to
transcriptional activation of the IL-6 promoter (Vanden Berghe et al., 1998). In
addition, inhibition of these pathways have been reported to repress TNF-mediated
IL-6 gene expression in L929sA cells (Vanden Berghe et al., 1998; Beyaert et al.,
1996t Furthermore, De Bosscher et al., (2001) showed that dex is able to inhibit the
amount of phosphorylated c-Jun N-terminal kinase (JNK), but not of phoshorylated
p38 or ERK in L929sA cells. To therefore determine whether the mechanism of MPA
repression involves interference with MAPK pathways, a range of Western blotting
experiments of L929sA cell Iysates was carried out after treatment with or without
TNF, in the presence of different steroid ligands as indicated. Results showed that
MPA, in contrast to dex and prog, was unable to inhibit the amount of phosphorylated
JNK p46 and p54 isoforms. Furthermore, the amount of phosphorylated p38 and
ERK MAPK was not affected by dex, MPA or prog. The results of these experiments
are discussed further in Chapter 4.
1 For References, see Manuscript.
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TNF - - - + + + - - - + + +
DEX flM - 1 10 - 1 10
MPA flM - 1 10 - 1 10
a) JNK
b) p38
c) ERK
I TNF
a) JNK
b) p38
c) ERK
Figure 8: MPA does not inhibit MAPK activity.
Effect of dex, MPA and prog on JNK, p38 and ERK phosphorylation levels in L929sA cells.
Cells were untreated or pre-treated with 1 or 10 flM dex, MPA or prog for two hours, followed
by incubation with or without TNF (2000 lU/mi) for 10 minutes. Cell Iysates were made and
activated a) JNK, b) p38, and c) ERK were detected using the corresponding phospho-
specific MAPK antibodies. The result shown is typical of three independent experiments. Non-
phospho-JNK was used to check for equal protein loading (data not shown).
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Pharmacological definitions
To characterise the way in which a ligand binds to its receptor and what
effects it will elicit in terms of transactivation and transrepression of genes, certain
parameters need to be determined. A full agonist is a drug or ligand that produces a
maximal response, whereas a partial agonist is a ligand or drug that provokes a
response less than the maximal response of that of a full agonist. An antagonist is a
drug that does not elicit a response itself, but blocks agonist-mediated responses.
The efficacy of a ligand is its ability to cause a response once bound to its receptor,
in other words, the maximal effect it can elicit in a given tissue under particular
experimental conditions. The potency of a ligand or drug is commonly quantified as
the EC50, the concentration that leads to half the maximal response and reflects both
the affinity of the ligand as well as its efficacy (Jenkinson et al., 1995; GraphPad
Prism software). The equilibrium dissociation constant (Kd or Ki) is a measure of the
affinity of a ligand for its receptor, and is equivalent to the concentration of ligand
required to bind to half the available receptors at equilibrium. Kd and Ki can be
interpreted the same way, and the subscript i is used to indicate that the competitor
inhibits radioligand binding. When the concentration of ligand equals the Kd or Ki,
half of the receptors will be occupied at equilibrium. When the receptors have a high
affinity for the ligand, the Kd or Ki will be low, as it will take a low concentration of
ligand to bind half the available receptors. The relative binding affinity (RBA), also
referred to as the EC50, is a measure of the concentration of competitor that
competes for half the specific binding. If the affinity (Kd or Ki) of a ligand for its
receptor is high, the EC50 will be low. Kd or Ki values however, represent a more
accurate measure of relative binding affinity of a ligand for its receptor than EC50
values. The Kd or Ki is a constant value for a particular receptor, not influenced by
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experimental variations, whereas the EC50 is a relative term, which is influenced by
different experimental conditions, including receptor number or radiolabelled ligand
concentrations. The EC50 obtained from competitive binding curves is thus not the
same as the Kd or Ki. Different EC50s can be obtained under different experimental
conditions, for the same receptor in the same tissue/cell sample. The relative EC50
values can also differ for two different competitors, for the same receptor in the same
tissue/cell sample, depending on the experimental conditions of the binding assay
(GraphPad Prism software).
Analysis of radioligand binding experiments is based on the law of mass
action. This model assumes that binding is reversible. The number of binding events
per unit of time = [Ligand].[Receptor].Kon, where Konis defined as the association rate
constant or on-rate constant. Once binding has occurred, the ligand-receptor
complex remains intact for a random amount of time. The probability of dissociation
is the same at every instant of time. The rate of dissociation is the number of
dissociation events per unit time = [liqand.receptorl.Kj., where Koft is defined as the
dissociation rate constant or off-rate constant. Equilibrium is reached when the rate
at which new ligand-receptor complexes are formed equals the rate at which the
ligand-receptor complexes dissociate. At equilibrium therefore,
[Ligand].[Receptor].Kon = [Ligand. Receptor]. Koft.If this equation is rearranged, the Kd
is defined as Koft/ Konwhich is also equal to [Ligand].[Receptor] / [Ligand. Receptor]
(GraphPad Prism software).
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Calculations of parameters
The conventional method used for calculating Kds is by saturation binding
experiments, ~here the concentration of radioligand is varied. An alternative method
is by homologous/heterologous competitive binding experiments, where the
radioligand concentration remains constant, and competes with varying
concentrations of unlabelled competitor ligand for the receptor. In the current study,
Kd and Ki values were determined by homologous and heterologous binding
experiments respectively (Chapter 3), since [3H] MPA and [3H] NET-A are not
commercially available. Kd and Ki values were obtained from pooled data of four
independent experiments, and were also represented relative to 100% binding by
dex to the GR (Chapter 3). Once it was determined that binding had reached
equilibrium, and that the EC50 was two to ten times larger than the concentration of
eH] dex used, Kd was calculated from homologous binding experiments by
GraphPad Prism software according to the following equation: Total binding =
(Bmax.[Hot]/ [Hot] + [Cold] + Kd) + NS, where NS is nonspecific binding. Once Kd for
dex was determined, heterologous binding experiments were performed where Ki
values for MPA, NET-A and prog were determined according to the Cheng-Prussoff
equation: Ki = EC50/ 1 + ([Iigand]/Kd), where the EC50 value is that determined for
the competing ligand, [ligand] is the concentration of radioligand used and Kd is
determined from homologous binding experiments. Binding data was analysed using
GraphPad Prism software. Briefly, the following parameters were chosen: Nonlinear
regression (curve fit), homologous competitive binding curve, one class of binding
sites, with weighting 1/y2 (which minimises relative distances squared), and the mean
y value of each point was considered. A stricter (slower) criterion for convergence
was used. Furthermore, runs test and residuals test were used to determine whether
the curve deviated systematically from the data.
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Another important parameter that was controlled for in this study was ligand
depletion. If a large fraction of the ligand binds to the receptors or binds non-
specifically, then the concentration of ligand free in the solution does not approximate
to the concentration added. Considering that this discrepancy is not the same in each
well, as a rule of thumb, less than 10% ligand depletion is considered satisfactory.
Ligand depletion in our experiments was always below 2%.
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Chapter 3
A comparison of the glucocorticoid agonist properties of the
synthetic progestins, medroxyprogesterone acetate and
norethisterone acetate
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3.1 Manuscript
Summary
The progestins, medroxyprogesterone acetate (MPA) and norethisterone
enanthate (NET-EN), are widely used as female contraceptive agents. In addition,
MPA and norethisterone acetate (NET-A) are popular compounds in hormone
replacement therapy (HRT). Surprisingly, it remains unknown whether doses of these
progestins used for contraception and HRT cause significant side effects through
various target genes via the glucocorticoid receptor (GR), and no thorough
comparison exists at the molecular level of their mechanism of action. By competitive
binding in whole cells, we show that both MPA and NET-A compete with
dexamethasone (dex) for binding to the endogenous human GR in lung carcinoma
A549 cells and transiently expressed rat GR in COS-1 cells. Equilibrium dissociation
binding constants (Kds) revealed that MPA displays a higher relative binding affinity
than NET-A and progesterone (prog) for the human GR (Kds of 4.2, 10.8, 270 and
215 nM for dex, MPA, NET-A and prog, respectively). By performing dose response
analysis for transactivation of a synthetic promoter-reporter construct containing
glucocorticoid (GC) response elements, we show that MPA displays greater GC
transactivation agonist potency than NET-A (EC50s of 1.1, 7.2, >1000 and 280 nM
for dex, MPA, NET-A and prog, respectively). Similarly, using an interleukin-8 (IL-8)
promoter reporter construct, we show that MPA displays greater GC transrepression
agonist potency than NET-A (EC50s of 0.21, 2.7, >100 and 26 nM for dex, MPA,
NET-A and prog, respectively). These results show that binding is a poor predictor of
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agonist potency. They also clearly demonstrate that these two synthetic progestins
exhibit very different GC-like properties and hence are likely to exhibit different side
effects via the GR, which may be particularly relevant to immune function and effects
on bone density.
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Introduction
The injectable progestagen-only contraceptives, medroxyprogesterone
acetate (MPA) and norethisterone enanthate (NET-EN), are the most widely used
female conventional contraceptives in South Africa. Although widely employed for
preventing pregnancy, these progestins have non-contraceptive uses as well. MPA is
used at higher doses in cancer therapy (Etienne et aI., 1992; Yamashita et aI., 1996),
while both MPA and norethisterone acetate (NET-A) are used in the treatment of
endometriosis (Irahara et aI., 2001; Harrison and Barry-Kinsella, 2000; Muneyyirci-
Delale and Karacan, 1998; Surrey and Hornstein, 2002) and in hormone replacement
therapy (HRT) (Brunelli et aI., 1996; Taitel and Kafrissen, 1995). In contraceptive
use, MPA is administered as a 150 mg aqueous suspension (referred to as Depo
Provera) every three months, whereas NET-EN is administered as a 200 mg oily
suspension every two months, both as intramuscular injections. After injection, MPA
is fairly stable and is itself the active contraceptive compound. However, NET-EN
and its acetate (NET-A) are hydrolysed to norethisterone (NET) and its metabolites,
which together with NET have contraceptive action (Stanczyk and Roy, 1990). Both
MPA and NET-EN are highly effective contraceptive agents in women due to their
multiple sites of action. MPA and NET-EN have both been shown to block ovulation
(Kaunitz, 2000; Greydanus et al., 2001; Bhowmik and Mukherjea, 1988) and alter the
content of cervical mucous to prevent sperm penetration (Greydanus et al., 2001;
Bhowmik and Mukherjea, 1987). Interestingly, both MPA and NET-EN in a
formulation with testosterone, are currently being tested as potential male
contraceptives. Since both LH and FSH are required for normal spermatogenesis,
both gonadotropins need to be suppressed, an effect which can be achieved with
MPA or NET-EN (Nieschlag et al., 2003).
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Both MPA and NET-EN have been shown to have several side effects
including irregular menses, amenorrhea, and headaches (Kaunitz, 2000; Greydanus
et aI., 2001; Benagiano et aI., 1978) when used as contraceptives in women. For
MPA, fatigue, bloating of the abdomen or breasts, behavioural changes, reduced
libido, weight gain, dizziness and possibly decreased bone density have also been
reported (Kaunitz, 2000; Greydanus et aI., 2001). The side effect profile of NET-EN is
assumed to be similar to but less severe than that of MPA. In particular, the return to
ovulation following the use of NET-EN occurs earlier (2.6 months) as compared with
MPA (5.5 months) (Benagiano et al., 1978; Koetsawang, 1991; Garza-Flores et al.,
1985). At high doses such as those used in cancer therapy, MPA has potent
glucocorticoid (GC)-like effects such as complete inhibition of adrenal function
(Blossey et aI., 1984; Papaleo et aI., 1984) and immunosuppression (Yamashita et
aI., 1996; Mallmann et aI., 1990; Scambia et aI., 1988). Furthermore, when used in
the treatment of endometriosis, MPA might be linked to an increased risk of
cardiovascular disease (Telimaa et aI., 1989). Doses of MPA used in HRT also
modulate immune function in women, selectively affecting various immune cell
subsets (Brunelli et aI., 1996; Malarkey et aI., 1997). Other side effects of MPA and
NET used in HRT include changes in the levels of lipids, lipoproteins and
vasomotion, which may increase cardiovascular risk (Sitruk-Ware, 2000) as well as
increase the risk of breast cancer in post-menopausal women (Riis et aI., 2002;
Stahlberg et aI., 2003). Furthermore, a large clinical trial on the risks and benefits of
an HRT regime (MPA combined with estrogen) in healthy menopausal women,
scheduled to run until 2005, was terminated early due to an increased risk of invasive
breast cancer. Increases in coronary heart disease, stroke, and pulmonary embolism
were also observed in participants on HRT. Although fewer cases of hip fractures
and colon cancer were reported, the overall health risks were found to be greater
than the benefits (Rossouwet aI., 2002). Recently published investigations also
suggested an increase in the risk of ovarian cancer (Anderson et aI., 2003).
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Given these established side effects, and the apparent arbitrary choice
between the use of MPA vs. NET as synthetic progestin in various reproductive
intervention treatments, it is surprising that very little information is available about
the molecular mechanism of action of MPA and NET, in particular their relative
properties. As both compounds are progestins, the physiological effects of MPA and
NET-EN are generally assumed to be mediated via the progesterone receptor (PR).
However, MPA has also been shown to have a high affinity and to be an agonist for
the glucocorticoid receptor (GR) (Teulings et al., 1980; Bojar et al., 1979; Feil and
Bardin, 1979; Bamberger et al., 1999). Furthermore, the affinity of the rat GR for
MPA (Kd = 5.0 nM) is similar to that of dexamethasone (dex) (Kd = 4.1 nM)
(Winneker and Parsons, 1981), but higher than that for the endogenous ligand,
cortisol (Kontuia et al., 1983). In the beagle dog, the Ki value (3.7 nM) was shown to
be only 4-5 times higher than that of dex, demonstrating a relatively high affinity for
the GR (Selman et al., 1996). In human mononuclear leukocytes, MPA was shown to
bind to the endogenous GR with a Kd of 31 nM, which was shown to be only 3 times
higher than that of dex (Kd = 10 nM) (Kontuia et al., 1983). For NET little is known
regarding its interaction with the GR. One study established relative binding affinity
from EC50 curves for NET, which displayed a very low binding activity (below 1%,
where dex = 100%) for the GR (Schoonen et al., 2000). Similarly, in another study,
NET showed very low binding affinity (0.1% determined from EC50 curves, relative to
dex) towards the GR in human mononuclear leukocytes (Kontuia et al., 1983).
Clearly, accurate Kds of MPA and NET for the GR (as related to the serum
concentrations found in patients on various treatments) would be useful information
in assessing their potential side effects via the GR.
Women receiving MPA by injection as a contraceptive in general have been
shown to have serum concentrations of about 1 ng/ml for the duration of
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contraceptive treatment (MishelI, 1996) i.e. about 2.6 nM. However, levels of drug-
related material have been reported to reach 25 ng/ml (65 nM) a few days post
injection (Kirton and Cornette, 1974). Contraceptive doses of NET-EN have been
reported to result in serum concentrations of about 1.5-59 nM (Fotherby et al., 1983).
Doses of MPA used for cancer therapy typically range between 500 and 1500 mg
orally per day for about 12 weeks (Blossey et al., 1984), for treatment of
endometriosis about 50- to 100 mg/day (Harrison and Barry-Kinsella, 2000; Telimaa
et al., 1989), while those used for HRT are about 10 mg/day for about 11 days
(Brunelli et al., 1996). From the literature, it is not clear what serum concentrations of
MPA women typically have during HRT use. Doses of NET used in HRT range from
about 0.35- to 2.1 mg orally per day (Taitel and Kafrissen, 1995). Women receiving
the Activelle HRT regime (0.5 mg NET-A, estradiol 1 mg daily) are reported to have
peak serum concentrations of NET ranging between 1.4- and 6.8 ng/ml (3.64- to 17.7
nM) after single dose administration (Activelle package insert reg. no.
33/21.8.2/0532, Novo Nordisk). For the treatment of endometriosis a daily dose of 5
mg of NET-A is used (Surrey and Hornstein, 2002). The extent to which these
various doses of progestins exert effects on various target genes in vivo via the GR is
not known.
The GR is a ligand-dependent transcription factor that belongs to the steroid
hormone receptor family. It is composed of an amino-terminal transactivation
(activation function-1, AF-1) domain (NTD), a central DNA-binding domain (DBD),
which interacts with the DNA response elements, and a carboxy-terminal domain,
which contains the ligand-binding (AF-2) domain (LBO) to which the steroid hormone
binds (Evans, 1988; Beato, 1989; Bledsoe et al., 2002). In an unbound state, the GR
resides in the cytoplasm and is complexed with several different protein factors
including heat-shock protein 90 (hsp90) (DeRijk et al., 2002) and immunophilins
(Davies et al., 2002). Upon hormone binding, receptor activation and phosphorylation
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occurs, resulting in translocation of the GR complex from the cytoplasm to the
nucleus where it dissociates, releasing GR to either transactivate or transrepress
specific genes (Davies et aI., 2002). There are at least three mechanisms through
which GCs can regulate gene transcription. The first involves activation of genes
through binding of GC-activated GR homodimers to consensus sequences referred
to as GC-response elements (GREs) found in the promoters of various genes
(Adcock, 2000; Webster and Cidlowski, 1999; Newton, 2000). The second
mechanism of GC-mediated regulation involves repression of target genes through a
direct interaction of GC-bound GR to variable negative GRE (nGRE) sequences
within the promoter (Adcock, 2000). Thirdly, GCs may inhibit other genes such as the
interleukin-8 (IL-8) gene by transcriptional cross-talk where the GR mutually
interferes with other signalling pathways such as those involving activator protein-1
(AP-1) and nuclear factor KB (NFKB) (Webster and Cidlowski, 1999; Karin, 1998; De
Bosscher et al., 2003; Mukaida et al., 1994).
In the current study, we performed whole cell binding assays and determined
the Kds of MPA and NET-A for the GR. In addition, we determined the relative
potencies and efficacies of these compounds for transactivation of synthetic GREs
and transrepression of an IL-8 promoter reporter gene via the GR.
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Figure 1: The steroid hormone carbon numbering system.
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Figure 2: The chemical structures of natural and synthetic progestins, and a
synthetic glucocorticoid. (A) medroxyprogesterone acetate; (B) norethisterone
acetate; (C) progesterone; (D) dexamethasone.
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Materials and methods
Cell culture, cytokines and inducing compounds
Human lung carcinoma A549 cells and human embryonic kidney Hek293
cells were a kind gift from Prof S. Okret (Karolinska Institute, Sweden) and were
maintained in 1:1 mixture of high glucose (1g/ml) DMEM (Sigma, South Africa) and
Ham-F12 (Highveld Biologicals, South Africa) medium supplemented with 10% FCS
(Highveld Biologicals, South Africa) and 50 lU/mi penicillin and 50 Ilg/ml streptomycin
(GibcoBRL, South Africa). Hek293 cells stably transfected with rat GR expression
vector were also provided by Prof S. Okret (Karolinska Institute, Sweden) and were
grown in complete medium described above, supplemented with hygromycin 100
Ilg/ml (Roche, South Africa). COS-1 cells were cultured in high glucose (1 g/ml)
DMEM (Sigma, South Africa) supplemented with 10% fetal calf serum (Highveld
Biologicals, South Africa), 50 lU/mi penicillin and 50 ~Lg/mlstreptomycin (GibcoBRL).
[3H] dexamethasone (89 Ci/mmol) was purchased from AEC-Amersham (South
Africa). Dexamethasone (dex) (9-alpha-fluoro-16-alpha-
methylprednisilone), medroxyprogesterone acetate (MPA) (6-alpha-methyl-17 -alpha-
hydroxyprogesterone acetate), progesterone (prog) (4-pregnene-3, 20-dione), and
norethisterone acetate (NET-A) (17-alpha-ethynyl-19-nortestosterone 17-beta-
acetate) were purchased from Sigma Aldrich, South Africa. We chose to use NET-A
since the acetate is soluble in water compared with the insoluble ester of NET-EN. In
vivo, both NET-EN and NET-A undergo hydrolysis and are converted to NET and its
metabolites (Stanczyk and Roy, 1990). The origin and activity of TNF has been
described previously (Vanden Berghe et aI., 1998). Hydroxyflutamide was obtained
from Dr C. Tendler (Schering Plough Research Institute, USA). Stock solutions were
routinely dissolved in ethanol and stored at -20°C.
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Plasm ids
The plasmid, pTAT-GRE-E1b-luc, driven by the E1b promoter that contains
two copies of the rat TAT-GRE, has been described previously (Tanner et al., 2003).
The rat GR cDNA (pSVGR1) (Delauney et al., 1996) was obtained from Prof S. Okret
(Karolinska Institute, Sweden). The plasmids, pCMV(3-gal and pSV(3-gal, were
obtained from Stratagene (South Africa) and Promega (South Africa) respectively.
The IL-8 promoter variant, p546hIL-8Iuc+, was kindly provided by Dr N. Mukaida
(Cancer Research Institute, Japan) (Mukaida et al., 1990).
Whole cell binding assays
Competitive whole cell binding assays were performed essentially as
described by Bamberger et al., (1995) with the following modifications. Briefly, A549
and COS-1 cells were maintained as above and seeded into 12-well tissue culture
plates (Nunc, South Africa) at 1.5 x 105 cells per well, in complete medium. On day
two, COS-1 cells were transiently transfected with pSVGR1 and pSV(3-gal using
FuGENE 6 according to manufacturer's instructions, whereas A549 cells remained
untransfected. On day three, the cells were washed three times with PBS warmed to
37°C and then incubated for three hours for A549 cells and one hour for COS-1 cells
at 37°C, with 1.25 nM for A549 cells, or 10 nM for COS-1 cells of [3H] dex (89
Ci/mmol) (Amersham, South Africa), in the absence and presence of varying
concentrations of unlabelled steroids diluted in medium without FCS, in a final
volume of 1 ml per well. Working on ice at 4°C, cells were washed three times with
ice-cold 1 x PBS containing 0.2% (w/v) BSA for 15 minutes. Cells were then lysed
with 200 ul Reporter Lysis Buffer (Promega Luciferase Assay System) and total
binding was determined by scintillation counting. Specific bound eH] dex was
calculated as the difference between total and non-specific binding, which was
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determined by incubating cells in the presence of eH] dex plus 500-fold excess
unlabelled dex. For A549 cells, the Bradford assay was used to determine total
protein concentration. For COS-1 cells, the f3-galactosidase assay (Galacto-Star™
assay system) was performed in a Labsystems Luminoskan RS luminometer.
Specific binding was therefore normalised to co-expressed f3-galactosidase activity
(for COS-1 cells) or total protein (for A549 cells). Binding data was analysed using
GraphPad Prism software (see Chapter 2 Appendix for calculation of parameters).
Transfections and dose-response curves
Transient transfection of COS-1 cells was performed with FuGENE 6 (Roche
Biochemicals, South Africa) according to manufacturer's instructions. Hek293 cells
were transiently transfected with p546hIL-8Iuc+ promoter reporter construct using
FuGENE 6 (Roche Biochemicals, South Africa) according to manufacturer's
instructions. Hek293 cells were also transiently transfected with the pTAT-GRE-E1 b-
lue construct and pCMV-f3gal where indicated, using polyethylenimine (PEl) (Aldrich,
South Africa) transfection method (Prof S. Okret, Karolinska Institute, Sweden,
personal communication). Briefly, cells were seeded at 6 x 104 cells per well in 24-
well tissue culture plates (Nunc, South Africa) and grown in complete medium. Cells
were left for at least 36 hours to reach optimal confluency of approximately 60%. For
transfection of each well, 0.5 ~LI(0.2 mM) PEl was added to 200 ng reporter DNA and
topped up to 20 ul with H20. The mix was then incubated for 10 minutes at room
temperature, followed by addition of 500 ul complete medium and incubation for 24
hours. Cells transfected with pTAT -GRE-E 1b-Iuc were incubated with or without test
compounds for 18 hours. Cells transfected with p546hIL-8Iuc+ were untreated or pre-
treated with dex, MPA or prog in the absence or presence of 2000 lU/mi TNF. Steroid
hormone was added two hours before TNF, for a total period of eight hours, after
which cells were lysed with Reporter Lysis Buffer (Promega Luciferase Assay
System) and assayed for luciferase and f3-galactosidase expression. The 0-
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galactosidase (Galacto-Star™ assay system) and luciferase assays (Promega
Luciferase Assay System) were performed in a Labsystems Luminoskan RS
luminometer. Where indicated, luciferase activity was normalised to co-expressed (3-
galactosidase activity to correct for differences in transfection efficiencies. Otherwise
where normalising to (3-galactosidase is absent, transfection efficiency was
previously determined to be highly reproducible. Data was analysed using GraphPad
Prism software. Briefly, the following parameters were chosen for dose-response
curve analysis: Nonlinear regression (curve fit), sigmoidal dose-response curve,
where the mean y value of each point was considered. A stricter (slower) criterion for
convergence was used. Furthermore, runs test and residuals test were used to
determine whether the curve deviated systematically from the data.
Statistical analysis
Statistical analyses were carried out using GraphPad Prism software, using
one-way analysis of variance with either Bonferroni (compares all pairs of columns)
or Dunnett (compares all columns vs. control column) posttests. In most figures,
statistical significance of differences is denoted by *, ** or ***, to indicate P<O.05,
P<O.01 or P<O.001, respectively. The letters a,b,c etc. are also used to denote
statistically significant differences, where all those values which differ significantly
(P<O,05) from others, are assigned a different letter.
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Results
MPA displays a higher relative binding affinity than NET-A for the GR.
To determine the relative binding affinity of MPA and NET-A for the rat GR,
competitive whole cell binding assays were preformed in COS-1 cells, transiently
transfected with rat GR expression vector. Homologous/heterologous curves were
analysed and EC50 values for each test compound determined and reported in
Figure 3a. Results show EC50 values of 9.6 ± 1.2 nM for dex, 17.1 ± 1.2 nM for MPA
and 153 ± 1.3 nM for NET-A. The EC50 values for dex and MPA differed 1.8-fold but
were found not to be statistically significantly different (p>0.05), whereas those for
dex and NET-A displayed a 16-fold statistically significant difference (p at least
<0.05). Furthermore, the EC50 values for MPA and NET-A differed 9-fold and were
also found to be statistically significantly different (p at least <0.05). No specific
binding was detected in the absence of transfected GR.
A similar trend in results was obtained for competitive whole cell binding
assays in A549 cells, which express GR endogenously. In order to obtain accurate
Kd and Ki values, a range of experiments was first carried out to establish two
important parameters. The incubation time required for equilibrium to be reached for
[3H] dex binding to the GR was determined as three hours, and an appropriate
concentration of eH] dex, in the range two to ten times lower than the EC50, was
established as 1.25 nM (data not shown). Homologous/heterologous curves with
unlabelled steroids were then established and results show that dex, MPA, NET-A
and prog are able to compete with [3H] dex for binding to the GR (Figure 3b). The
curves for each competitor steroid indicate competitive binding to the same site as
dex (R2 values for each MPA, NET-A and prog were 0.9978, 0.9728 and 0.9806
respectively, for one site competitive binding curve).
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Figure 3A: MPA and NET-A both compete with [3H] dex for binding to the rat GR.
COS-1 cells were transiently transfected with the pSVGR 1 and pSV~-gal expression vectors.
Cells were incubated twenty-four hours later with 10 nM [3H] dex in the absence and presence of
increasing concentrations of dex (a), MPA (A) or NET-A (+) for one hour. Competition for binding is
illustrated by the percent of eH] dex specifically bound to the rGR (normalised to ~-gal expression).
Results shown are averages of three independent experiments, where each condition was performed
vs. MPA (p>O.OS); MPA vs. NET-A (p<O.OS).
in triplicate (±SEM). In table, data was analysed to obtain ICSO values ± SEM for binding curves. Dex
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DEX 4.2 x 10-9 ± 1.1
MPA 1.08 X 10-8 ± 1. 1
NET-A 2.7 x 10-7 ± 1.3
PROG 2.15 x 10-7 ± 1.1
Figure 38: MPA, NET-A and prog compete with [3H] dex for binding to the human GR.
A549 cells were incubated with 1.25 nM [3H] dex in the absence and presence of increasing
concentrations of dex (.), MPA (.), NET-A (+) or prog (T) for three hours. Competition for binding is
illustrated by the percent of [3H] dex specifically bound to the hGR (normalised to total protein). Results
shown are representative of four independent experiments, where each condition was performed in
triplicate (±SEM). In the table, data from four independent experiments was analysed to obtain Kd or Ki
values ± SEM. Dex vs. MPA (p<0.001); MPA vs. NET-A (p<0.001); MPA vs. prog (p<0.001); NET-A vs.
prog (p>0.05).
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The displacement curves were analysed and Kd values determined for dex, and Ki
values determined for each MPA, NET-A and prog (Figure 3b). Dex was found to
have a Kd of 4.2 ± 1.1 nM for the GR, whilst MPA (Ki = 10.8 ± 1.1 nM) displayed a
2.6-fold lower binding affinity than dex (p<O.001). NET-A (Ki = 270 ± 1.3 nM) showed
a 64-fold lower binding affinity for the GR compared with dex (p<O.001). The Ki
values for MPA and NET-A were found to differ 25-fold and are also statistically
significantly different (p<O.001). Prog showed a similar Ki (215 ± 1.1 nM) for the GR
to that of NET-A (P>0.05). A549 cells express androgen receptor (AR) and GR
endogenously, but have been reported not to express PR (Zhang et aI., 2000). Since
MPA and NET are known to bind to the AR (Kemppainen et al., 1999; Deckers et al.,
2000), A549 cells were incubated with eH] dex and MPA in the presence or absence
of the AR antagonist, hydroxyflutamide. Results showed no difference in [3H] dex
binding to the GR in the presence of MPA co-treated with or without hydroxyflutamide
(data not shown). This suggests that the levels of AR are too low to interfere with the
GR-binding assay (data not shown). This also rules out the involvement of the AR in
our incubations with NET-A, since both MPA (EC50 = 6.79 x 10-9 M) and NET-A
(EC50 = 2.73 x 10-8 M) have been shown to display statistically similar binding
affinities towards the AR (unpublished data). We were unable to repeat the above
binding experiments in Hek293 cells, as these cells were technically difficult to
handle and would not have survived the various rigorous and necessary washes of
the binding assay. We were unable to determine accurate Ki values in COS-1 cells
as an excess concentration of [3H] dex was used and whether binding equilibrium
was reached was not determined (GraphPad Prism software).
MPA displays much greater GC agonist potency and efficacy than NET -A for
transactivation.
To compare the relative GC properties of MPA and NET-A for transactivation,
Hek293 cells stably transfected with a rat GR expression vector, were transiently
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transfected with a GRE-driven reporter construct (containing two copies of the rat
TAT GRE). Cells were subsequently treated with increasing concentrations of dex,
MPA, NET-A or prog. Results showed greatest transactivation with dex, followed by
MPA and followed by prog (Figure 4a). NET-A, even at a concentration of 10 ).lMwas
unable to transactivate the promoter reporter construct in our system (Figure 4a). To
determine the relative potency and efficacy between the steroidal ligands, dose-
response curves were analysed and EC50 and maximal values for each test
compound were determined. Dex showed the greatest potency for transactivation
with an EC50 value of 1.1 ± 1.0 nM, followed by MPA (EC50 = 7.2 ± 1.1 nM) which
displayed a 6.5-fold lower potency than dex, followed by prog (EC50 = 280 ± 1.1 nM)
with a 39-fold lower potency than MPA. MPA and prog were unable to transactivate
to the same maximal extent as dex, showing that they are partial agonists for
transactivation via the GR.
To determine whether the above transactivation results are dependent on the
presence of the GR, transient transfections with the same GRE-driven reporter
construct were also performed on wild-type Hek293 cells (not stably transfected with
GR). Cells were treated with 10 ).lMdex, MPA, NET-A or prog and results showed no
transactivation in the absence of stably transfected GR (Figure 4b), showing that the
results obtained in Figure 4a were due to the presence of the GR.
Transactivation studies were also performed on COS-1 cells transiently
transfected with a 2xGREtkluc reporter construct (containing 2 copies of a GRE
upstream of the tk promoter) with and without rat GR cDNA, in the presence of
steroid hormone. Results show that dex, like MPA, is able to transactivate the
reporter at concentrations as low as 1nM (Figure 4c). Significant transactivation of
the GRE-driven reporter by 2.6 nM, a concentration typically observed in the serum
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of women using MPA as a contraceptive (MishelI, 1996), was also obtained with dex
or MPA (Figure 4d). Interestingly, MPA showed greater GC activity than cortisol, the
endogenous ligand for the GR, at both concentrations tested (Figures 4c and 4d).
Furthermore, this effect was clearly dependent on the presence of the GR. In the
presence of the rat GR, no transactivation was observed with NET-A at
concentrations up to 10 ).lM (Figures 4d and 4e).
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Figure 4: MPA, unlike NET -A, displays partial agonist activity via the GR.
Hek293 cells, either stably transfected with the rat GR expression vector (A) or wild-type (B) were
transiently transfected with the pTAT-GRE-E1b-luc reporter. For (A), cells were incubated in the
absence and presence of increasing concentrations of dex (a), MPA (.), NET-A (t) or prog (T) for
eighteen hours. In the table, data from three independent experiments was analysed to obtain EC50 ±
SEM and maximal values ± SEM for each test compound. Oex vs. MPA (p<0.001); MPA vs. prog
(p<0.001). For (B) cells were incubated in the absence or presence of 10 11Mdex, MPA, prog or NET-
A for eighteen hours. In (C, 0, and E), COS-1 cells were transiently transfected with the pTAT-GRE-
E1b-Iuc and pCMV-~gal expression vectors, with or without pSVGR 1. Cells were then incubated for 24
hours in the absence or presence of 1 nM (C), 2.6 nM (D) test compound or as indicated (E). For (A-
E), results shown are representative of three independent experiments where each condition was
performed in triplicate (±SEM). For (B-E), statistical significance of differences is denoted by *, ** or
***. Induction is expressed in relative light units (rlu). For some experiments (A, B), only luciferase (luc)
values were determined. For others (C-E), luc values were normalised for ~-galactosideas (luc/ê-qal).
N/A = no activity up to 10-5 M NET-A.
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MPA displays much greater GC agonist potency and efficacy than NET-A for
trans repression.
To compare the relative GC properties of MPA and NET-A for
transrepression, Hek293 cells stably transfected with a rat GR expression vector,
were transiently transfected with an IL-8 promoter reporter construct, p546hIL-8Iuc+.
Cells were subsequently treated with TNF and increasing concentrations of dex,
MPA, NET-A or prog. To determine the relative potency and efficacy between the
steroidal ligands, dose-response curves were analysed and EC50 and maximal
values for each test compound were determined. Dex showed the greatest potency
for transrepression with an EC50 value of 0.21 ± 1.2 nM, followed by MPA (EC50 =
2.7 ± 1.2 nM), which showed a 13-fold lower potency than dex (p<0.001), followed by
prog (EC50 = 26 ± 1.1 nM) with a 10-fold lower potency than MPA (p<0.001) (Figure
5a). NET-A showed very little repression of the promoter reporter construct (Figure
5a). MPA repressed the promoter to almost the same maximal extent as dex, while
the maximal effect of prog was slightly less than that of MPA.
To determine whether the above transrepression results are GR-dependent,
transient transfections with the same IL-8 promoter reporter construct were also
performed on wild-type Hek293 cells not stably transfected with GR. Cells were
treated with 10 f.!M dex, MPA, NET-A or prog and showed no transrepression in the
absence of stably transfected GR (Figure 5b).
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Figure 5: MPA acts as a potent agonist for transrepression via the GR, while NET-A acts as a
very weak partial agonist.
Hek293 cells, either stably transfected with the rat GR expression vector (A) or wild-type (8) were
transiently transfected with the p546hIL-8Iuc+ reporter. For (A), cells were incubated in the absence
and presence of increasing concentrations of dex (.), MPA (A), NET-A (+) or prog (T) whereas in (8)
cells were incubated in the absence or presence of 10 11Mdex, MPA, prog or NET-A. For both (A) and
(8), incubations were performed in the absence or presence of 2000 lU/mi TNF. Steroid hormone was
added two hours before TNF, for a total period of eight hours, after which cells were lysed and
assayed for luciferase expression. In (A) luciferase activity for each test compound condition was
normalised relative to the activity of the reporter in the presence of TNF and in the absence of test
compounds, which was taken as 100%. In table, data was analysed to obtain EC50 ± SEM and %
repression values ± SEM for each test compound. Dex vs. MPA (p<0.001); MPA vs. prog (p<0.001).
For (A), results shown are representative of three independent experiments where each condition was
performed in triplicate (±SEM). For (8), results shown are averages of four independent experiments
with each condition in triplicate (±SEM). For (8), the letters a,b,c etc. are used to denote statistically
significant differences, where all those values which differ significantly (P<0,05) from others, are
assigned a different letter. Induction is expressed in relative light units (rlu). N/A = no activity up to 10.5
M NET-A.
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Discussion
Ideally, a drug targeted to the PR should display similar properties as prog in
terms of binding affinity and agonist activity towards the PR and other receptors. To
date, no thorough comparison exists at the molecular level of the mechanism of
action of MPA vs. NET or NET-A. In particular, a comparison of the relative binding
affinity (relative equilibrium dissociation constants) and relative potency and efficacy
for transactivation and transrepression of these two progestins and prog towards the
GR has not been previously reported.
Our results show that both MPA and NET-A bind to the GR in A549 cells and
that they bind to the same site as that of dex. Interestingly, prog was also observed
to bind to the GR with a relative binding affinity similar to NET-A. Furthermore, we
determined accurate equilibrium dissociation constants, which show that MPA
displays a higher relative binding affinity than NET-A for the GR. A similar trend of
results was obtained in COS-1 cells transiently transfected with the rat GR
expression vector as is reflected in the relative EC50 values. The results in COS-1
cells strongly support our binding data obtained in A549 cells and confirm that the Ki
values determined are due to the binding of test compounds to the GR and not to any
other steroid receptors. To our knowledge, our study is the first to establish accurate
Ki values for both MPA and NET-A towards the human GR. Our Kds for dex and
MPA (4.2- and 10.8 nM, respectively) for the human GR, are slightly lower than the
previously reported Kds of 10- and 31 nM respectively, also for the human GR
(Kontuia et al., 1983), and are slightly higher than the previously reported Kds for the
dog GR (0.8- and 3.7 nM, respectively) (Selman et al., 1996). However, the
previously established Kds of 4- and 5 nM for dex and MPA respectively, for the rat
GR (Winneker and Parsons, 1981) agree well with our results, and suggest that there
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are no substantial species differences between the rat and human GR towards
binding affinity of MPA and dex. Our results with NET-A are consistent with the study
by Schoonen et aI., (2000) who show a low relative binding affinity of NET and its
metabolites for the human GR (below 1%, where dex = 100%) in human leukemic
IM-9 cells. It is unclear from that data whether the relative binding activity was
determined from Kd values or from ECSO curves.
Previously we observed significant transactivation by MPA of a GRE-driven
promoter reporter construct in both L929sA mouse fibroblast and COS-1 cells. These
effects of MPA were shown to be mediated at least in part via the GR (submitted for
publication, Chapter 2). In the current study, we investigated relative agonist activity
of MPA and NET-A for transactivation via the GR. Our results show that MPA and
prog act as partial agonists for transactivation of a GRE-driven promoter reporter
construct in Hek293 cells and this effect is clearly dependent on the presence of
stably transfected GR. We found however, that NET-A was unable to induce the
reporter even at the highest concentrations (10 f.lM) used. This is consistent with
results obtained in COS-1 cells transiently transfected with a GRE-driven promoter
reporter construct. Interestingly, these COS-1 cell experiments were also previously
carried out using a simple GRE-driven promoter reporter construct (2 x GREtkluc)
yielding similar results, indicative of the absence of promoter-specific effects (data
not shown). ECSO values extrapolated from the dose-response curves performed in
Hek293 cells show that dex displayed the greatest potency for transactivation,
followed by MPA, which showed a 6.S-fold lower potency than dex, followed by prog
which had a 39-fold lower potency than MPA (Table 1).
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MPA NET-A PROG
relative binding
affinity in A549 41.0±3.39 1.68 ± 0.42 2.00 ± 0.10
cells
(%)
relative potency
for 15.5±1.73 N/A 0.40 ± 0.05
transactivation
(%)
relative efficacy
for 72.2 ± 0.85 0.40 ± 0.01 64.3 ± 2.46
transactivation
(%)
relative potency
for 7.90 ± 1.29 0.211 0.80±0.10
transrepression
(%)
relative efficacy
for 95.4 ± 1.16 23.0 ± 3.44 88.7 ± 0.66
transrepression
(%)
Table 1: Relative binding affinity from Kd or Ki values in Figure 3b, relative EC50
(potency) and relative maximal values (efficacy) for both transactivation (from Figure
4a) and transrepression (from Figure 5a). All values are percentages, calculated
relative to 100% activity of dex ± SEM. N/A = no activity up to 10.5 M NET-A. 1 This
EC50 could not be determined with as much accuracy as the other values, due to the
shallow slope.
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We also investigated the relative agonist activity of MPA and NET-A for
transrepression of IL-8 via the GR. IL-8 belongs to a chemotactic cytokine family and
is responsible for the chemotactic migration and activation of neutrophils,
lymphocytes, monocytes and other cell types at sites of inflammation (Mukaida et aI.,
1994; Feghali and Wright, 1997). Furthermore, GC-mediated repression of IL-8
genes has been shown to involve the GR (Mukaida et aI., 1994). We have shown
previously that MPA and prog, like dex, significantly represses TNF-stimulated IL-8
promoter reporter constructs at the transcriptional level in L929sA cells, an effect
thought to be mediated at least in part via the GR. In this study, our results show that
dex, MPA and prog act as agonists for transrepression of the IL-8 promoter reporter
construct in Hek293 cells and this effect is clearly dependent on the presence of
stably transfected GR. We found however, that NET-A only repressed the induced
reporter by 22% at the highest concentrations (10 11m)used. Furthermore, EC50
values extrapolated from the dose-response curves performed in Hek293 cells
showed that dex displayed the greatest potency for transrepression. In addition, MPA
showed a 13-fold lower potency than dex, followed by prog and NET-A, which had a
10-fold and about 38-fold lower potency than MPA respectively (Table 1).
When assessing the dissociative properties of each test compound, the
relative efficacies of MPA, NET-A and prog for transrepression were found to be
significantly greater than their respective efficacies for transactivation. The difference
in efficacy of MPA relative to dex for transrepression is 95% and for transactivation is
75% (Table 1). The transrepression/transactivation ratio for MPA therefore is 1.3
which is similar to that of dex used as the standard (transrepression/transactivation =
1) (Bamberger and Schulte, 2000). We conclude that MPA discriminates only slightly
between transactivation and transrepression for the rat GR in Hek293 cells. This
result is similar to our previous findings for the endogenous mouse GR in L929sA
cells where the ratio for MPA was calculated as 1.5 (submitted for publication,
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Chapter 2). However, in the studies by Bamberger et al., (1999) and Bamberger and
Schulte, (2000), MPA behaved as a dissociated GC, as it only marginally
transactivated a GRE-reporter construct in human Hela cells and in normal human
lymphocytes, via the endogenous GR in both cell types. In normal lymphocytes, MPA
showed a transrepression/transactivation ratio of 6.6, compared with dex where the
ratio was 1 (Bamberger and Schulte, 2000). The differences between these results
and those of the present study could be due to tissue-specific effects as previously
discussed (submitted for publication, Chapter 2). Similarly to MPA, we found the
transrepression/transactivation ratio for prog to be 1.4. However, for NET-A, the
transrepression/transactivation ratio was calculated as 55 showing significantly
greater dissociative GC properties compared with MPA and prog, although it was
only a very weak partial agonist for transrepression.
When comparing the relative binding affinities of MPA and NET-A towards the
GR with their relative potencies and relative efficacies for transactivation and
transrepression, the fold differences relative to dex display interesting findings (Table
1). In terms of rank order for dex, MPA and prog, the ligand that binds with greatest
affinity to the GR is the more potent agonist for transactivation and transrepression
and displays the greatest efficacy. However, the extent to which each ligand binds
relative to dex does not reflect the extent to which it is an agonist for transactivation
or transrepression. MPA, prog and NET-A showed 41%, 2% and 1.7% binding
affinities respectively, relative to 100% binding by dex, towards the GR. However,
both MPA and prog showed significantly lower relative potencies for transactivation
with 15.5% (2.6 times lower) for MPA and 0.4% (5 times lower) for prog, relative to
100% potency for dex. Although NET-A is able to bind to the GR (binding affinity
1.7%, relative to 100% binding with dex), it failed completely at transactivating the
promoter reporter construct at 10 J..lM.Similarly, there is no exact correlation between
Kds and relative efficacies for transactivation, nor between Kds and relative
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potencies or efficacies for transrepression. Interestingly, for MPA the relative potency
observed for transactivation (15.5%) was almost 2-fold higher than its potency
reported for transrepression (7.9%), relative to 100% potency for dex. In contrast, the
trend for prog was the other way around where the relative potency for
transactivation (0.4%) was 2-fold lower than the potency for transrepression (0.8%),
relative to 100% potency of dex. Although NET -A showed no activity for
transactivation, the relative EC50 for transrepression was estimated as about 0.21 %.
Thus, for MPA, prog and more so for NET-A, binding affinity appears to be a poor
indicator of the extent of ago~ist potency and efficacy for transactivation and
transrepression.
Determinants of ligand-specific bioactivity for the GR are not fully understood,
but appear to be influenced by a number of factors, which modulate activation and
activity of the GR in a multi-step process. The first step involves the ability of the
ligand to recognise and bind the GR, which is influenced by the chemical structure
(discussed below) of the ligand as well as the affinity of the ligand for the GR. The
affinity of a ligand for its receptor has been shown to be one of several determinants
of potency (Chen et al., 2002). Ligand binding induces a conformational change of
the GR, suggested to be to be dependent on the affinity of the ligand for the GR
(Schaaf and Cidlowski, 2003). The GR has been shown to undergo a differential
conformational change upon binding of different ligands (Vicent et al., 2002). These
ligand-specific differences in GR conformation may affect the potency of the GR-
ligand complex, possibly due to the recruitment of different co-factors. The stability of
steroid-GR complexes, which is dependent on specific steroid receptor contacts, also
influences the ability of GCs to stimulate the transactivation function of the GR
(Hellal-Levy et al., 1999). Furthermore, the dissociation rate of the ligand from the
GR (as has been shown for dex) is a reflection of the transactivation function of the
GR (Hellal-Levy et al., 1999). Once bound to ligand, receptor phosphorylation occurs
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and the GR translocates into the nucleus where it either transactivates or
transrepresses specific genes with the assistance of various co-factors. Differences
in nuclear translocation, in terms of distinct pathways of receptor trafficking and
processing within the nucleus, and retention of the liganded-GR in the nuclear
compartment, are also thought to influence ligand-specific responses (Defranco,
2002; Vicent et al., 2002). Furthermore, it has been shown for same agonists and
antagonists that the amount of ligand-induced phosphorylation of Ser211 in the
liganded GR correlated with the transcriptional activity of the GR (Wang et al., 2002).
There is also evidence in the literature that ligand-specific co-factor recruitment may
also influence transcriptional regulation (Coghlan et al., 2003; Miner, 2002). Finally,
the dissociation rate of liganded-GR from DNA may reflect ligand potency (Pandit et
al., 2002). It is thus possible that additional information on other influencing factors as
described above may reveal a more direct correlation for agonist potency and/or
efficacy for dex, MPA, NET-A and prog via the GR.
Clearly the chemical structure of a ligand influences its binding specificity
towards and transcriptional potency via the GR. This is now better understood since
the crystal structure of the GR LBO has recently been solved (Bledsoe et al., 2002).
Although structurally the GR has been shown to share over 50% identity with the
androgen receptor (AR), progesterone receptor (PR) and estrogen receptor (ER) in
its amino acid sequence and three-dimensional structure, many subtle differences
exist in their secondary structure and topology of their ligand-binding pockets
(Bledsoe et al., 2002). Regions encompassing helices 6 and 7 have been shown to
be key determinants of ligand binding and transactivation potential of receptors (Wan
et al., 2001). Helices 6 and 7 of the GR have been shown to deviate significantly from
the ER, AR and PR and produce a unique side pocket in the GR. This pocket is
thought to account for the GR selectivity of GCs, which have larger substituents at
the C17 (carbon 17) position com pared with estrogen, prog, and testosterone
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(Bledsoe et al., 2002). Steroid selectivity appears to be influenced by the
complementarity of shape and hydrogen bonding between ligands and the ligand-
binding pocket in the GR.
The main determinant of GR binding affinity appears to be dependent on tight
association between the steroidal A-ring and the GR, with the presence of a 4-en-3-
one moiety in the A-ring being essential (Ouax et aI., 1988). The orientation of the A-
ring relative to the B-, C- and O-rings also appears to be particularly important for the
GR, since there is evidence that the GR prefers an A-ring that is turned towards the
alpha-face, i.e. where the A-ring is bent underneath the plane defined by the B-, C-
and O-rings (Duax et aI., 1988). The C3 ketone (A-ring) of steroid hormones is also a
prominent feature of steroid A-ring recognition and has been shown to accept
hydrogen bonds from 0(glutamine)570 and R(arginine)611 in the GR crystal
structure (Bledsoe et aI., 2002; Hammer et aI., 2003). While functional groups at the
B-, C- and O-rings playa minor role in affinity, they appear to play an important role
in determining whether a ligand is an agonist or an antagonist, as well as agonist
potency (Duax et aI., 1988). In the case of the GR, the hydroxyl groups at positions
C11, C17 and C21, as found in dex and cortisol, are particularly important in
contributing to agonist potency, most likely due to their hydrogen bonding properties.
They are not required for binding, but for subsequent activation functions. The
presence of an 11-beta hydroxyl appears to slow down the rate of dissociation of the
ligand from the GR (Duax et al., 1988), which could affect its transactivation function
(Hellal-Levy et al., 1999). In addition, the N564 of the GR forms a hydrogen bond to
the C11-hydroxyl group (C-ring) of GCs, and is shown to be important for target gene
activation, as well as ligand binding (Hammer et aI., 2003), although the latter effect
appears to be controversial. The 17-alpha-hydroxyl group (O-ring) of dex forms a
specific hydrogen bond with 0642 in the GR structure (Bledsoe et al., 2002).
Furthermore, the presence of C17- and C21-hydroxyl groups, allows the O-ring to
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accept one hydrogen bond to oxygen (e.g. 0 at C20), and to donate two hydrogen
bonds (e.g. at C17 and C21) (Ouax et al., 1988).
When interpreting our binding and activity data in light of the above, it seems
not surprising that dex binds to the GR with a high affinity and is a potent agonist,
while progesterone binds with a lower affinity and is a weak partial agonist. While
both steroids contain a 4-en-3-one in the A-ring, the tighter binding of dex as
apposed to prog is most likely due to the bending of its A-ring towards the alpha-face,
facilitated by the presence of the 9-alpha-fluoro group, and the extra double bond in
the A-ring (Ouax et al., 1988), plus possibly the C11-hydroxyl, features which are all
absent in prog. The relatively weak GR-agonist properties of prog, similar to what has
been found for testosterone (Ouax et al., 1988), most likely stems from the absence
of the hydroxyl groups at positions C11, C17 and C21, which are present in dex.
It is however more difficult to understand why MPA, unlike NET-A, binds so
tightly and is an agonist for the GR. They both contain a 4-en-3-one in the A-ring,
which most likely accounts for their binding to the GR. The presence of the two
methyl groups on the A- and B-ring, respectively, for MPA, which are absent in NET-
A, may explain the differences in binding affinity. It is possible that these two methyl
groups result in a more optimal orientation of the A-ring with respect to the other
rings, than for NET-A. Indeed it has been shown that the C6-methyl group of MPA
plays a role in increasing the relative binding affinity of MPA for the GR, relative to
prog (Kontuia et al., 1983). MPA, like NET-A, lacks a C11-hydroxyl group, and the
presence of hydrogen bond donors at C17 in the O-ring. Thus while this could
contribute to the lack of agonist activity for NET-A, it is hard to understand why MPA
is an agonist. The reason most likely lies in the differences between their functional
groups at C17. At this position, NET-A has an ethynyl group, which is a large
inflexible hydrophobic group, and may pose a steric hindrance and interfere with
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optimal interactions in the GR ligand-binding pocket, further contributing to the lack of
agonist activity of NET-A. One explanation for the agonist potency of MPA could be
that the acetate may be rapidly hydrolysed, either enzymatically or non-enzymatically
by participation of the neighbouring functional groups, resulting in a free C17-
hydroxyl group, which could donate a hydrogen bond. Even if this occurs, MPA would
still lack the C11-hydroxyl, which thus appears not to be essential for agonist activity.
It is interesting to speculate that, since MPA has a greater efficacy for
transrepression than transactivation, the contribution to conformation facilitated by
hydrogen bonding to the C11-hydroxyl is not as important for transrepressioin as
compared to transactivation. While NET-A, as for MPA, could also be hydrolysed in
our experiments, it may be that the rate of hydrolysis of MPA is greater than that for
NET-A, since the ketone at C20 of MPA (absent in NET-A), may assist in the
hydrolysis of the acetate. If both MPA and NET-A are predominantly in the
hydrolysed form in our assays, then the differences in agonist activity could be due to
the non-optimal steric orientation of the C17-hydroxyl of NET-A, which is in the beta
orientation compared with the alpha orientation of that of MPA and dex. Furthermore,
the presence of the ketone as a hydrogen bond acceptor for hydrolysed MPA,
compared with the hydrophobic ethynyl group of NET-A described above, may also
explain the greater agonist activity of MPA. Further experiments using radiolabelled
steroids could be performed to investigate these hypotheses.
Taken together, our data show that MPA displays significantly higher potency
and efficacy than prog for transactivation of GREs and for transrepression of IL-8. In
contrast, NET-A shows no agonist activity for transactivation of GREs while it acts as
a very weak partial agonist for transrepression in our system. Given the
multifunctional nature of IL-8 (Feghali and Wright, 1997; Mukaida et aI., 1994;
Barclay et al., 1993), our results suggest that MPA may exert significant side effects
via repression of this gene on inflammation or on the immune response. Other genes
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involved in immune function which are also repressed by GCs via similar
mechanisms may also be targets for MPA regulation via the GR. Moreover, several
genes involved in other physiological responses are also negatively regulated by
GCs, and may be targets for MPA, such as the a-subunit of glycoprotein hormones
(Chatterjee et al., 1991), prolactin (Sakai et al., 1988) and osteocalcin (Stromstedt et
al., 1991). Our results also suggest that MPA may exert side effects in various cells
via transactivation of target genes containing GREs. This may be of particular
importance since transactivation may be the predominant mechanism by which GCs
exert many of their metabolic and cardiovascular side effects (Imai et al., 1993;
Brasier and Li, 1996).
When considering the potential physiological implications of our results for
patients taking various doses of MPA or NET-A for therapy, or MPA and NET-EN for
reproductive intervention, it is likely that free concentrations of MPA as low as 10 nM
in a target cell could potentially occupy a significant percentage of GRs. The total
serum concentrations of up to 65 nM MPA in contraceptive users could thus
potentially result in significant levels of GR occupancy in some target cells, although
the free concentrations of MPA would also depend on the concentrations of serum
binding proteins, their affinity for MPA as well as the concentrations and affinities of
endogenous competing steroids. The extent of GR occupancy would also naturally
depend on the concentrations and affinities of endogenous steroids competing for
GR binding, as well as the nature and extent of steroid metabolism in the cell. The
potential for GR mediated side effects in HRT users would most likely be even
greater than for contraceptive users, given the higher cumulative doses. With respect
to NET, it would appear that a concentration of about 25-fold greater than that for
MPA would be required for similar GR occupancy, and that such occupancy would
not result in GR activity, but rather in antagonistic effects. It is also possible that
higher concentrations of MPA and NET are achieved in selected target tissues than
Stellenbosch University http://scholar.sun.ac.za
156
in serum, such as their storage in fatty tissue, which may also be dependent on their
relative stability. Although we cannot predict from our in vitro data to what extent
MPA and NET will cause significant effects via the GR in vivo, our results certainly
provide a molecular basis for formulating hypotheses, which can be tested in further
studies. Most importantly however, these results show clearly that MPA and NET-A
differ greatly from each other and from prog in their GC-like effects in vitro and thus
potentially also in their physiological effects via the GR in vivo.
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Appendix 2
Data not included in manuscript
We showed in Chapter 2 that MPA repressed Il-6 and Il-8 promoter reporter
constructs at the transcriptional level, via interference with NFKB and AP-1. We also
showed that MPA, like dex, did not affect NFKB DNA-binding activity. Since
interference with NFKB DNA-binding activity has been shown to be one mechanism
that may account for inhibition of NFKB (Vanden Berghe et al., 2000; De Bosseher-et
al., 2003)1 and since NET-A, like MPA has been shown to bind to the GR (Chapter
3), we were interested to compare its effects relative to dex and MPA at the NFKB
DNA-binding level. Figure 4 shows the results of a gel shift experiment in 1929sA
cells where 1 ).lM NET-A like MPA and dex, had no effect on the DNA-binding activity
of NFKB. Similar results were obtained for Hela cells (data not shown). These results
are discussed in Chapter 4.
1For References, see Chapter 2.
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TNF + + + + +
DEX + +
MPA + +
Prog + +
NET-A + +
- p50p65
RBP-JK
Figure 4: MPA and NET-A do not interfere with the DNA-binding activity of NFKB.
L929sA cells were untreated or pre-treated with 1 f.lM dex, MPA, prog or NET-A for two hours
in the absence or presence of 2000 lU/mi TNF for 30 minutes. Total cell extract was
incubated with an NFKB-specific oligonucleotide and protein-DNA complexes were analysed
in an electrophoretic mobility shift assay (EMSA) (see Chapter 2 for method). The result
shown is typical of two independent experiments. RBP-JK is the constitutively expressed
recombination binding protein. p50p65 is the activated NFKB complex.
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Chapter 4
Discussion and concluding remarks
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4.1 Summary and discussion of results presented in this
thesis
In this thesis the interaction of MPA and NET-A with the GR, and their effects
on interleukin gene expression were investigated. MPA at high doses, such as those
used in HRT (Brunelli et aI., 1996; Malarkey et aI., 1997) and cancer therapy
(Yamashi~a et al., 1996; Mallmann et al., 1990; Scambia et al., 1988), has been
shown to exert immunosuppressive side effects in patients. Furthermore, Bamberger
et aI., (1999) recently reported that MPA at 2.5x10-7 M repressed transcription of a
human IL-2 promoter reporter construct in normal human lymphocytes, to the same
extent as dex, suggesting GR involvement.
The first part of this thesis was therefore aimed at investigating the effects of
MPA relative to dex and prog, on interleukin gene expression, and the molecular
mechanism of action thereof, with a view to shedding light on its immunosuppressive
effects. As shown in Chapter 2, MPA, like dex and prog, significantly repressed TNF-
stimulated IL-6 protein production, and IL-6 and IL-8 promoter reporter constructs at
the transcriptional level. This appears to be the first report showing repression of IL-8
promoter activity by MPA. Towards further investigating the molecular mechanism of
repression of the IL-6 and IL-8 promoters by MPA in L929sA cells, a number of
experiments were carried out which revealed interesting and novel findings. Firstly,
as a number of pro-inflammatory genes contain NFKB and/or AP-1 sites in their
promoters or regulatory regions (De Bosscher et aI., 2003), whether the repressive
effect of MPA could affect activity of these transcription factors was investigated.
Results in this study showed for the first time that the inhibitory action of MPA on
interleukin gene expression involved interference with NFKB and AP-1 transcription
factors (Chapter 2).
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The molecular mechanism whereby MPA interferes with NFKB activity was
further investigated, in particular its effects on NFKB DNA-binding activity. Previous
studies have demonstrated that the GR represses NFKB-driven genes without
affecting DNA-binding activity of NFKB (De Bosscher et al., 1997; Vanden Berghe et
al., 1999). Since MPA has a high affinity for the GR, and since we proposed that
MPA may be acting at least partly via the GR, its effects relative to dex and prog at
the NFKB DNA-binding level were compared. As NET-A is also used widely in
reproductive therapy, its effect was also investigated (Chapter 3 Appendix). Results
showed that, like dex, MPA, prog (Chapter 2) and NET-A (Chapter 3 Appendix)
treatment of TNF-induced 1929sA cells could not disrupt DNA-binding by NFKB.
Similar results were observed in Hela cells. These findings are consistent with a
mechanism of action of MPA and NET-A via the GR, since previous reports have
shown that the GR bound to dex also does not disrupt DNA-binding by NFKB in vitro
(De Bosscher et al., 1997; Vanden Berghe et al., 1999; Nissen and Yamamoto,
2000) and in vivo (Nissen and Yamamoto, 2000). However, this result does not
exclude the involvement of other receptors. Interestingly, others have shown that
although dex-activated GR does not inhibit TNF-stimulated pre-initiation complex
assembly at the Il-8 and ICAM-1 promoters, it does interfere with phoshorylation of
serine 2 of the RNA polymerase" carboxy-terminal domain (Nissen and Yamamoto,
2000). Similar mechanisms may therefore be responsible for MPA- or NET-A-
mediated repression of TNF-stimulated Il-6 and Il-8 gene expression in 1929sA
cells.
The effects of MPA on the activity of MAPK pathways were investigated with
a view to further understanding its molecular mechanism of action. TNF-activated
p38 and ERK MAPK pathways have been shown to contribute to transcriptional
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activation of the Il-6 promoter (Vanden Berghe et al., 1998). TNF-activated p38 and
ERK are known to activate mitogen and stress activated protein kinase-1 (MSK-1),
which associates with and phosphorylates the p65 subunit of NFKB, thus activating
the transcription factor (Vermeulen et aI., 2003). TNF-activated JNK is thought to play
a role in Il-6 promoter activity by phosphorylating c-jun and thus activating AP-1
transcriptional activity (De Bosseher et al., 2003). To determine whether the
mechanism of MPA repression involves interference with MAPK pathways, the
effects of MPA on JNK, p38 and ERK signalling were investigated in Chapter 2
(Appendix). Results showed that MPA, in contrast to dex and prog, was unable to
inhibit the amount of phosphorylated JNK p46 and p54 isoforms. Furthermore, the
amount of phosphorylated p38 and ERK MAPK was not affected by dex, MPA or
prog. The result with dex is consistent with the results of De Bosscher et al., (2001)
who showed that dex inhibits the amount of phosphorylated JNK, but not
phoshorylated p38 or ERK in 1929sA cells. Similarly, dex was reported to prevent
phosphorylation and subsequent activation of JNK in Hela cells (Caelles et al., 1997;
Gonzalez et al., 2000) and in human and murine endothelial cells (Gonzalez et al.,
1999). Also consistent with the result for dex is the report of Gonzalez et al., (1999)
showing that dex is unable to inhibit TNF-activated p38 signalling pathways in
endothelial cells. Our results indicate that, although MPA appears to mimic the
effects of dex and prog in repression of Il-6 and Il-8 promoters, subtle differences in
the mechanisms of action of these compounds may occur. The finding that MPA
behaves differently as compared to prog, while prog behaves similarly to dex, in their
effects on JNK is very interesting. If the effects of dex, MPA and prog are mediated
predominantly via the GR in these cells, then one would expect that MPA would give
a similar result to dex, and greater than prog, since MPA is a more potent GC than
prog (see later). However, if the effects of prog were mediated predominantly via the
PR, then one would expect MPA to give a similar response to that of prog, since
MPA is at least as potent an activator of the PR as prog. These results suggest that
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receptors other than the GR and PR may be involved in the JNK response. A recent
exciting report in the literature provides evidence that differences in the effects of
MPA vs. prog on MAPK signalling may play an important role in neurological
processes. Estrogen has been shown to have neuroprotective effects against
glutamate neurotoxicity through activation of MAPK signalling, resulting in nuclear
ERK activation. Not only was MPA shown to be an ineffective neuroprotectant, it also
attenuated estradiol-induced neuroprotection when co-administered. In contrast to
prog and estradiol, MPA-activated ERK was shown to remain cytosolic with no
nuclear signal, resulting in a lack of neuroprotection (Nilsen and Brinton, 2003).
These observed differences indicate that all progestins are not alike in their
mechanism of action and may have serious health implications in vivo.
In order to determine which steroid receptors are involved in the above effects
of MPA on regulation of interleukin genes in the L929sA cells, a combined approach
involving the use of receptor-specific antagonists, as well as nuclear translocation
studies were performed. Since high concentrations of ligand were required to obtain
significant transrepression, we were unable to use receptor-specific antagonists to
determine the receptors mediating the transrepressive effects of MPA, because at
these concentrations, RU486 and hydroxyflutamide acted as agonists for
transrepression. However, these receptor-specific antagonists did not display agonist
properties for transactivation. In MPA-mediated transactivation of a GRE-driven
promoter reporter construct, we were able to exclude the involvement of the AR.
Since we observed no PR activity for transactivation using R5020, we were also able
to exclude involvement of the PR, supporting a role for the GR in mediating in part
the transcriptional effects of MPA (Chapter 2). This was further supported by our
immunofluorescence results showing that MPA causes nuclear translocation of the
GR (Chapter 2). In our transrepression studies, we were however, unable to exclude
the involvement of the AR or the PR-A isoform, which is a poor activator of
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transactivation, but a potent activator of transrepression (Kalkhoven et al., 1996).
Furthermore, we could not exclude the possible participation of other receptors like
the MR or pregnane X receptor (PXR) in MPA-mediated transactivation and
transrepression. Further experiments would therefore be necessary to determine the
possible involvement of other receptors (see 4.2).
Although NET-EN (or NET-A) is as widely used as MPA in reproductive
therapy, to date no proper pharmacological characterisation of the relative efficacy
and potency of the two progestins on gene regulation via the GR has been reported.
Furthermore, no thorough comparison exists on the relative binding affinity of MPA
vs. NET (or NET-A) towards the GR. Considering that MPA has been shown to bind
with high affinity to the GR, AR, and PR (Teulings et al., 1980; Bentel et al., 1999;
Kemppainen et al., 1999; Bojar et al., 1979; Bergink et al., 1983; Feil and Bardin,
1979) and as the above results in L929sA cells in Chapter 2 could not show
conclusively that the transrepressive effects of MPA were mediated exclusively via
the GR, the next part of the thesis was performed in a more suitable experimental
model system. In Chapter 3 therefore, most of the work was carried out in Hek293
and COS-1 cells transfected with the rat GR. These cells do not express significant
levels of endogenous steroid receptors, and allow the possibility of doing negative
control experiments in the absence of transfected GR, unlike L929sA cells which
express endogenous GR, PR and AR (Jung-Testas et al., 1976). To investigate and
compare meticulously the agonist properties for both transrepression and
transactivation of MPA, NET-A and prog via the GR, EC50 curves were established
where possible, each with a wide range of concentration points, and reproducible
EC50 values were extrapolated from each curve to determine the relative potency of
each progestin. The results (Table 1) clearly indicate that MPA displays a
significantly greater GC agonist potency and efficacy than NET-A and prog for both
transactivation and transrepression via the rat GR, in Hek293 cells stably transfected
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with rat GR. For clarity of discussion these cells will now be referred to as 'Hek293 +
GR' in this chapter.
Hek293 + GR MPA NET-A PROG
cells
Relative potency
for 15.5± 1.73 NfA 0.40 ± 0.05
transactivation
(%)
Relative efficacy
for 72.2 ± 0.85 0.40 ± 0.01 64.3 ± 2.46
transactivation
(%)
Relative potency
for 7.90 ± 1.29 0.21 0.80±0.10
trans repression
(%)
Relative efficacy
for 95.4 ± 1.16 23.0 ± 3.44 88.7 ± 0.66
trans repression
(%)
L929sA cells MPA NET-A PROG
Relative potency
for 62.5 ± 14.5 NfO 6.64 ± 2.80
transactivation
(%)
Relative efficacy
for 48.0 ± 1.44 NfO 16.0 ± 0.74
transactivation
(%)
Relative potency
for 27.5 ± 9.80 NfO 5.22 ± 1.52
trans repression
(%)
Relative efficacy
for 74.4 ± 1.57 NfO 75.4 ± 2.20
trans repression
(%)
Table 1: Relative EC50 (potency) and relative maximal values (efficacy) ± SEM, for
both transactivation and transrepression in L929sA cells (Chapter 2) and Hek293 +
GR cells (Chapter 3). All values are percentages, calculated relative to 100% activity of dex
± SEM. NfA = no activity up to 10-5 M NET-A. NfD = not determined.
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Equilibrium binding studies were carried out to determine for the first time
precise Ki values as a measure of relative binding affinity of MPA, NET-A and prog
for the GR. Extensive optimisation experiments were initially performed, including the
determination of the time required to obtain binding equilibrium as well as a suitable
concentration of radiolabelled ligand, to enable Kds to be obtained from competitive
binding curves. It is often easier to obtain relative binding affinity values from EC50
curves instead, which provide less accurate relative binding affinity values than Kd or
Ki values.
Results showed that MPA, NET-A and prog were able to compete with dex for
binding to the GR in A549 cells, and MPA (Ki = 1.08 x 10-8 M) displayed a higher
relative binding affinity than NET-A (Ki = 2.7 X 10-7 M) and prog (Ki = 2.15 x 10-7 M)
towards the receptor. A similar trend of results for MPA and NET-A was obtained in
COS-1 cells. Collectively, these results show that MPA behaves as a GR agonist in
our experimental model system, whereas antagonist-like properties of NET-A
towards the GR were observed, since it binds to the GR but displayed no or very
weak partial agonist activity for transrepression only. However, due to its low binding
affinity for the GR, NET-A would only be able to compete with endogenous GCs and
thus antagonise the GR when present at relatively higher concentrations. Taken
together, our results with MPA and NET-A may have significant physiological
implications in vivo, since many genes in various biological processes are regulated
by the GR, which is ubiquitously expressed. Such processes include genes involved
in reproduction (Chatterjee et al., 1991; Sakai et al., 1988), immune (Spangelo and
Gorospe, 1995; Galon et al., 2002) and adrenal function (Drouin et al., 1993) and
bone metabolism (Ishida and Heersche, 2002).
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A comparison of the results obtained in 1929sA (Chapter 2) and Hek293 +
GR cells (Chapter 3) provide interesting insights into the dissociative properties of
MPA, prog and NET-A, and possible cell-specific effects (Table 1). Although GCs
have been widely used since the late 1940s for the treatment of excessive
inflammation, the molecular mechanisms responsible for their anti-inflammatory
activity are still under investigation. Transactivation is considered to be the
predominant mechanism by which GCs exert many of their side effects (Imai et aI.,
1993; Brasier and li, 1996). This has led to a search for novel GCs, referred to as
'dissociated GCs', which selectively transrepress pro-inflammatory genes with
relatively little transactivation of other genes, thus reducing the potential risk for
systemic side effects (Adcock, 2003). MPA showed significant transactivation of a
GRE-driven promoter construct in both 1929sA (via the endogenous mouse GR) and
Hek293 + GR cells (via expressed rat GR), whereas prog only showed significant
transactivation in Hek293 cells. Unlike MPA and prog, NET-A showed no
transactivation in Hek293 cells. When comparing the dissociative GC properties of
MPA as compared to dex in both 1929sA and Hek293 + GR cells, similar results
were observed. In 1929sA cells, the fold differences relative to dex for
transrepression and transactivation efficacy are 0.74- and OA8-fold respectively. The
transrepression/transactivation ratio for MPA therefore is 1.5, which is similar to that
of dex used as the standard (transrepression/transactivation = 1) (Bamberger and
Schulte, 2000). Similarly, in Hek293 + GR cells the fold differences relative to dex
efficacy for transrepression are 0.95-fold, and for transactivation 0.72-fold, yielding a
transrepression/transactivation ratio of 1.3. From this data we may conclude that
MPA discriminates only marginally between transactivation and transrepression in
both mouse 1929sA and Hek293 + rat GR cells in this study. These findings are in
contrast to the results of Bamberger et aI., (1999) and Bamberger and Schulte,
(2000), where MPA behaved as a dissociated GC, as it showed only marginal
transactivation of a GRE-reporter construct in Hela cells and in normal human
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lymphocytes, via the endogenous human GR in both cell types. MPA showed a
transrepression/transactivation ratio of 6.6 in normal human lymphocytes, compared
with dex where the ratio was 1 (Bamberger and Schulte, 2000). Similarly, in mouse
hepatoma BTWG3 cells, MPA was not able to transactivate the p(GRE)250hluc+
promoter construct via endogenous GR, in contrast to the results for dex (Allie et al.,
unpublished results). These differences could, as has been shown for GCs, be due to
cell-specific differences as described in Chapter 2. In addition, differences in receptor
expression levels (Bamberger et al., 1996) may also affect the
transrepression/transactivation ratio and thus the dissociative GC properties of a
compound. As discussed in Chapter 1, transactivation requires dimerisation of the
GR (Adcock, 2000), whereas a GR monomer is sufficient for transrepression (Radoja
et al., 2000). Therefore, under conditions where receptor levels are limited,
transactivation may be inhibited to a greater extent than transrepression. This could
explain the results observed by Bamberger et al., (1999), where the dissociative
effect of MPA was dependent on GR expression levels. When normal lymphocytes
were co-transfected with human GR, the transactivating effect of MPA was
enhanced, and a subsequent loss of dissociative GC properties was observed
(Bamberger et al., 1999). It is therefore possible that L929sA and Hek293 + GR cells
express higher levels of GR than lymphocytes or hepatoma cells. Although MPA has
been implicated as a promising agent for the treatment of autoimmune and/or
inflammatory disease (Bamberger et al., 1999), the results of the present study
indicate that further investigations into its potential dissociative GC activity are
necessary. When assessing the dissociative GC properties of NET-A compared to
dex in Hek293 + GR cells in the current study, the transrepression/transactivation
ratio was calculated as 55, showing significantly greater dissociative GC properties
compared with MPA and prog, although it displayed very weak partial agonist activity
for transrepression only at high concentrations. Based on these findings, NET-A does
not appear to be a potential compound for use as an anti-inflammatory drug. When
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comparing the dissociative GC properties of prog relative to dex in both L929sA and
Hek293 + GR cells, the transrepression/transactivation ratio in L929sA cells was
determined as 0.75/0.16 = 4.7. In Hek293 + GR cells, this ratio was calculated as
0.89/0.62 = 1.4. These results indicate that prog acts as a stronger dissociated GC in
L929sA cells, whereas its dissociative profile in Hek293 + GR cells is more similar to
that of MPA. This observed difference may be due to a number of cell-specific
variations as described above for MPA. Furthermore, prog may also be metabolised
in a cell-specific manner. Another possible explanation for this may involve the
presence of different receptor isoforms. Prog may therefore be mediating its
transactivation effects via the PR-A isoform (a poor activator of transactivation, but a
potent activator of transrepression) present in L929sA cells, resulting in a greater
dissociative ratio. This theory holds only if PR-A is present at low levels in L929sA
cells relative to GR protein. If greater levels of PR-A were present, then MPA would,
like prog, show significantly greater dissociative GC properties in L929sA cells (a
greater ratio than 1.5) compared with Hek293 + GR cells. Although prog displays
dissociative GC properties in one model system in this study, it is involved in many
biological processes in vivo and would not be an ideal candidate for anti-
inflammatory treatment. More suitable compounds like non-steroidal selective GR
agonists (SEGRAs) have recently been reported to show dissociative properties in
human cells, several of which are now in clinical development (Adcock, 2003).
Dose-response experiments performed in L929sA (Chapter 2) and Hek293 +
GR cells (Chapter 3) revealed further interesting cell-specific differences in response
to the same steroids. When comparing the relative potencies (to dex) and relative
efficacies (to dex) of both MPA and prog in L929sA vs. Hek293 + GR cells for
transactivation and transrepression, a statistically significant trend was observed
(Table 1). Firstly, the potency of MPA (relative to dex as 100%) for both
transactivation and transrepression was significantly greater (4- and 3.5-fold
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respectively) in L929sA cells compared with Hek293 + GR cells. Similarly, the
potency of prog (relative to dex as 100%) for both transactivation and transrepression
was also significantly greater (16.6- and 6.5-fold respectively) in L929sA cells
compared with Hek293 + GR cells. In contrast, the efficacies of MPA and prog
(relative to dex as 100%) for both transactivation and transrepression were greater
(1.5- and 1.3-fold respectively for MPA, 4- and 1.2-fold respectively for prog) in
Hek293 + GR cells compared with L929sA cells. The above results may be explained
by a number of cell-specific factors thought to influence ligand potency and/or
efficacy. To begin with, such factors may include variations in receptor content, which
could influence the relative potency and relative efficacy for transrepression in
L929sA cells compared with Hek293 + GR cells. L929sA cells have been reported to
express GR, AR and ER (Jung-Testas et aL, 1976), and we also detected PR mRNA
and protein in our cells by RT-PCR and Western blotting (data not shown).
Furthermore, MPA has been shown to bind to the GR, PR and AR (Teulings et al.,
1980; Bentel et al., 1999; Kemppainen et al., 1999; Bojar et al., 1979; Bergink et al.,
1983; Feil and Bardin, 1979) and prog has been shown to bind to the PR and GR
(Chapter 3; Kontuia et al., 1983). A role for the ER in L929sA cells can be excluded,
as it is well established that MPA does not bind to the ER (Teulings et al., 1980).
Although our results in Chapter 2 suggest that the GR is responsible for mediating
the transactivation effects of MPA and prog in L929sA cells, additional receptors may
be responsible for mediating the transrepressive activity of these compounds in these
cells. In Hek293 + GR cells however, we showed that all the observed transcriptional
effects of MPA were exclusively due to the presence of the GR (Chapter 3).
Intracellular hormone availability may also be an influencing factor in the
observed differences in relative efficacy and relative potency in the two cell types
investigated. As the Hek293 cell line was derived from human embryonic kidney cells
and since L929sA cells are of mouse fibroblast origin, there may be significant
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variation in steroid metabolism within these cell types. Intracellular hormone
availability may also be regulated cell-specifically by variations in expression levels of
the transporter proteins LEM1 or MDR1, which actively and specifically export GCs
from the cell (Kralli et al., 1995; Bourgeois et al., 1993). Furthermore, variations in the
receptor protein such as mutations, or ratio of GRu-AlB isoforms (de Lange et al.,
1997; Yudt and Cidlowski, 2001), may affect ligand-binding affinity of the receptor or
ligand-receptor complex stability (Hurley et al., 1991; Ashraf and Thompson, 1993)
and thus may influence ligand potency vs. efficacy. In addition, post-translational
modifications (Wallace and Cidlowski, 2001; Bamberger et al., 1996; Galigniana et
al., 1999; Poukka et al., 2000; Kyriakis, 2000), alternative receptor dimerisation
(Savory et al., 2001) and receptor co-chaperones (Schneikert et al., 2000) may also
affect ligand potency and/or efficacy in a cell-specific manner. Expression levels of
hsp proteins (Bamberger et al., 1996) may also influence GR function. Furthermore,
cell-specific cross-talk between MAPK signalling and steroid receptors (Kyriakis,
2000), DNA-binding of activated GR complexes and recruitment of other nuclear
factors (Bamberger et al., 1996; Chen et al., 2002) may also play influencing roles.
All these above points highlight the importance of characterising pharmacologically
new or potential drugs in various model systems to gain an improved understanding
of potential biological effects.
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4.2 Future perspectives
One area of possible future investigation would be to determine which steroid
receptors playa role, and to what extent, in the responses to MPA and NET-A in
L929sA cells, by using receptor-specific antagonists. This approach would also be
useful in other model cell systems, but can be limited by the availability and
specificity of such antagonists, as well as their cell-specific effects. For example,
RU486 acts as an agonist in some cells and as an antagonist in others (Bamberger
and Chrousos, 1995). Another useful approach could be the use of antibodies, where
available, to identify specific receptor isoforms. In the first part (Chapter 2) of this
thesis, we were unable to determine conclusively which receptor(s) was responsible
for mediating the IL6 and IL8 transrepressive effects of MPA in L929sA cells.
Although we observed no PR activity for transactivation using R5020, a strong PR
agonist, the transrepressive effects of MPA may have been mediated in part via the
PR-A isoform. Furthermore, the AR may also have been implicated in the
transrepressive effects of MPA. These possibilities remain to be investigated. A GR-
specific antagonist (006) has recently been developed (Miner et al., 2003) which
could be used in the place of RU486, which does not discriminate between PR and
GR, to determine which receptor is involved in mediating the transrepressive effects
of MPA. In addition, it would be interesting to determine which of the different
isoforms of the GR (Yudt and Cidlowski, 2001) might also be involved. Other likely
receptor candidates, which could be investigated as potential mediators of
transcription by MPA, may include the MR, as MPA has been shown to bind the
receptor (Wambach et al., 1979), or PXR (Moore et al., 2002). Therefore, a more
thorough investigation in L929sA cells in terms of establishing receptor content and
presence of receptor isoforms would be applicable.
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It would be interesting to investigate in more detail the mechanism whereby
MPA, NET-A and prog inhibit NFKB and AP-1 driven promoters and how this relates
to their effects on JNK, p38 and ERK. Furthermore, it would be of interest to
determine what possible differences exist between the effects of MPA, NET-A and
prog on these pathways. Further experiments in L929sA cells or other suitable model
systems could include an investigation into the effects of MPA, NET-A and prog on
MAPK activation including phosphorylation, nuclear translocation and genomic/non-
genomic effects. Time course studies could also be included. Furthermore, GC-
dependent repression of NFKB-driven genes has been proposed to be mediated by
increased synthesis of IKB-a, which could subsequently sequester NFKB in the
cytoplasm in an inactive form. The effects of MPA and NET-A on mRNA and protein
levels of IKB-a, the cytoplasmic inhibitor of NFKB could be studied, in L929sA cells or
other model systems.
In the second part of this thesis (Chapter 3), the relative binding affinity of
MPA towards the GR was investigated in A549 cells, as Hek293 cells could not be
used due to technical complications. In addition to being easy to handle technically (a
necessary requirement for this type of assay), another advantage to using A549 cells
was that they express GR endogenously, which eliminated the requirement for
transfection. Although suspected to be present at low levels, one limitation to using
these cells was thought to be the presence of endogenously expressed AR (Zhang et
al., 2000), which was controlled for in this study by using the AR antagonist,
hydroxyflutamide. It would therefore be appropriate to perform the binding
experiments in a more robust batch of Hek293 + GR cells, thus ensuring that all the
assays (competitive binding, transactivation, transrepression) are performed within
the same system. In this way the results would be influenced by the same cell-
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specific factors. Failing to perform the binding experiments in Hek293 + GR cells, all
the assays described above could be carried out in a new system, responsive to low
concentrations of steroid and where only GR is endogenously expressed. In addition
to investigating the equilibrium dissociation constant for each MPA and NET-A, their
dissociation rates from the GR could also be investigated. These results may better
reflect their relative agonist potency and efficacy. Such studies may provide more
insights into the relationship between binding parameters and biological potency.
Prior to this thesis, no thorough pharmacological characterisation of the
relative efficacy and potency of MPA vs. NET (or NET-A) on gene regulation via
specific steroid receptors had been performed. Furthermore, no thorough comparison
exists in the literature on the relative binding affinity of MPA vs. NET (or NET-A)
towards the AR, PR, MR or PXR. Additional experiments could therefore be
performed where the relative binding affinity and dissociation rates of MPA and NET-
A as well as their relative agonist properties for transactivation and transrepression
on target genes are investigated via various receptors within the same system. This
could be done for each of the PR, AR, MR and PXR. Such work would be vital in
gaining a better understanding at the molecular level of the immunosuppressive and
other possible side effects of MPA vs. NET (or NET-A) .. PXR is a promiscuous
nuclear receptor that has evolved to protect the body from toxic chemicals by
responding to a wide variety of prescription drugs, xenobiotics and endogenous
compounds (Watkins et al., 2002) including dex, prog and DHT (Moore et al., 2002).
PXR stimulates the transcription of cytochrome P450 3A monooxygenases (CYP3A)
and other genes involved in the detoxification and elimination of these potentially
harmful chemicals (Goodwin et al., 2002). It would be interesting to determine
whether MPA and/or NET-A used in reproductive therapy have the capacity to
modulate PXR activity, and thus potentially influence the metabolism and elimination
of other drugs taken concurrently.
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In addition to the results obtained in this thesis, work in this area has already
been initiated in our laboratory on the AR and MR. Bath MPA and NET-A have been
shown to compete with [3H] mibolerone for binding to the human AR co-transfected
into COS-7 cells (Africander et al., unpublished results; Tanner et al., unpublished
results). However, further investigations are currently underway to obtain precise Ki
values for both MPA and NET-A. MPA and NET-A also displayed similar androgen
agonist activity in COS-7 cells transiently co-transfected with a GRE-driven promoter
construct and human AR, and EC50 values for each progestin are currently being
established (Africander et al., unpublished results). Furthermore, MPA, unlike NET-A
and DHT, was unable to induce the ligand-dependent NIC interaction of the AR, a
result in agreement with that reported by Kemppainen et al., (1999). Yet similarly to
DHT, MPA and NET-A were both able to induce the ligand-dependent interaction of
the co-activator, SRC-1, with the AF2 domain (Tanner, MSc Thesis). Further studies
could be performed to determine the relative agonist potency for transrepression of
MPA vs. NET-A of various interleukin genes, such as IL-6 and IL-8, via the AR.
Furthermore, the relative binding affinity of MPA and NET-A in COS-1 cells for co-
transfected MR has also been investigated. In contrast to Wambach et al., (1979),
results showed that MPA and NET-A were unable to compete with [3H] aldosterone
for binding to the MR. Furthermore, transactivation experiments in COS-1 cells
transfected with an MR expression vector and the MMTV-Iuciferase reporter
construct demonstrated that MPA and NET-A were devoid of either agonist or
antagonist activity (Africander et al., unpublished results). Such studies will serve to
improve our understanding of the potential role of various steroid receptors in the
responses of various cells to MPA and NET-A, since most cells contain a mixture of
steroid receptors, present at varying relative concentrations.
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4.3 Concluding remarks
Although their precise molecular mechanisms of action are not well defined,
millions of women worldwide use MPA and NET-EN as contraceptives, and MPA and
NET-A in HRT, while MPA is also used in cancer treatment. The importance of
understanding the mechanism of action of different synthetic progestins is becoming
increasingly evident, especially in light of recent clinical trials showing that long-term
use of MPA in combination with estrogen in HRT presents more risks than benefits
(Rossouwet aI., 2002). Recent evidence suggests that MPA, used as contraceptive,
increases viral shedding (Mostad et aI., 1997), raising concerns about the impact of
its use on sexually transmitted diseases. Another important recent finding is that
MPA, unlike prog, may have deleterious effects on neurological processes (Nilsen
and Brinton, 2003). Clearly, further investigations are required at a molecular level to
shed light on the mechanism of action of synthetic progestins, including their
interaction with steroid-binding proteins such as serum proteins, steroidogenic
enzymes and steroid receptors. In addition, their tissue-specific intracellular signalling
mechanisms, including genomic and non-genomic effects, metabolism, activation of
kinase pathways, and target genes involved, need to be further investigated.
The experiments presented in this thesis focus on the effects of MPA and
NET-A on interleukin gene expression and their interaction with the GR. These
results imply that MPA, unlike NET-A, use in vivo may exert GC-like
immunosuppressive side effects, via genes with NFKB or AP-1 in their promoters, via
the GR. The results also suggest that MPA, unlike NET-A, use in vivo may result in
the upregulation of various genes with GREs in their promoters. Considering that
serum concentrations of MPA in contraceptive users can reach up to 65 nM, and that
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MPA was shown in Chapter 3 to have a Kd of 10 nM, it could potentially occupy a
significant fraction of GRs in vivo and elicit various side effects.
By a careful comparison of binding, agonist potency and efficacy data, the
results obtained in this study enabled GR ligand-specific relationships between these
parameters to be examined, revealing that binding affinity is not a reliable indicator of
agonist potency or efficacy for transactivation or transrepression of these
compounds. These, as well as the JNK results, also highlight the point that all
progestins are not alike, nor similar to prog, in their mechanism of action.
Furthermore, the results obtained in this study also revealed interesting cell-specific
differences for MPA, NET-A and prog.
Clearly much more work needs to be done to further our understanding of the
mechanism of action of synthetic progestins. However, combining the existing
physiological and molecular information available on MPA and NET-A action with the
results presented in this thesis, can contribute to a better understanding of the effects
of these progestins in vivo. Such insights may provide women and their clinicians
with more information to facilitate the selection of method of contraception or HRT.
Furthermore, these insights into mechanisms of action could also facilitate improved
drug design for contraceptive agents and reproductive therapy regimes.
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